Talazoparib
Protocol C3441037Final Protocol Amendment 1, [ADDRESS_534553] ON 
PHARMACOKINETICS OF THE PROPOSED TALAZOPARIB SOFT GEL
CAPSULE FORMULATION IN PARTICIPANTS WITH ADVANCED SOLID 
TUMORS
Study Intervention Number: PF-06944076
Study Intervention Name: [CONTACT_423192]:
EudraCT Number: 2020-006101-35
Protocol Number: C3441037
Phase: 1
Short Title: A Phase [ADDRESS_534554] study for the proposed talazoparib soft gel capsule formulation in participants with advanced solid tumors
This document and accompanying materials contain confidential information belonging to [COMPANY_007]. Except as 
otherwise agreed to in writing, by [CONTACT_22788], you agree to hold this information in confidence and not copy or disclose it to others (except where required by [CONTACT_1289]) or use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, [COMPANY_007] 
must be promptly notified.
CCI
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 2PROTOCOL AMENDMENT S UMMARY OF CHANGES TA BLE
Document History
Document Version Date Summary and Rationale for Changes
Amendment 1 22June 2021 The primary  purpose of the amendment is 
to incorporate initial design assumptions
reassess ment during the trial .The
previous estimation of power/ sample size
was based on the AUC 24variance of the 
current commercial formulation as no
clinical data was available for the 
proposed soft gel capsule formulation and 
assumed ratio 1.07. In addition, previous ly 
issued Protocol Administrative Change
Letters and clarifications were
incorporated in this amendment. All 
modifications are summarized below.
The cover page is updated with the 
EudraCT number due to the inclusion 
of sites in European Union.
Synopsis, Sections 4.1, 9.2 and 9.4.2
are updated to include the 
reassessment of initial design 
assumptions and potential sample 
sizerevision.
Section 4.1 is updated to clarify  the 
definition of unstable renal function .
Section 5.1, #2b is updated to clarify  
criteria 
for participants with ovarian 
cancer, #2c is updated to clarify
criteria for pa rticipants with NSCL C 
with EGFR mutations.
Section 5.2, #18 and 21 are updated 
to clarify  the washout periods for 
compounds with long half- lives .
Section 6.2, #8 is up dated to clarify  
the number of units required for 
sample retention to align with the 
FDA guidance .
Section 10.[ADDRESS_534555] the drugs with long half -lives and 
no potential for DDI with talazoparib.
Original protocol 29July 2020 N/A

Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June [ADDRESS_534556] of country  healthy  authorities and IRBs/ECs and any protocol administrative 
clarification letter.

Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June [ADDRESS_534557] OF FIGURES ...................................................................................................................9
1. PROTOCOL  SUMMARY ...................................................................................................10
1.1. Sy nopsis ..................................................................................................................10
1.2. Schema ....................................................................................................................14
1.3. Schedule of Activities .............................................................................................15
2. INTRODUCTION ...............................................................................................................21
2.1. Study  Rationa le.......................................................................................................21
2.2. Background .............................................................................................................21
2.2.1. Clinical Overview .......................................................................................23
2.3. Benefit/Risk Assessment
.........................................................................................24
2.3.1. Risk Assessment
.........................................................................................24
2.3.2. Ben efit Assessment .....................................................................................25
2.3.3. Overall Benefit/Risk Conclusion ................................................................25
3. OBJECTI VES, ESTIM
ANDS, AND ENDPOINTS ...........................................................26
4. STUDY DESIGN .................................................................................................................26
4.1. Overall Design .........................................................................................................26
4.2. Scientific Rationale for Study  Design .....................................................................27
4.2.1. Participant Input Into Design ......................................................................31
4.3. Justification for Dose ..............................................................................................32
4.4. End of Study  Definition ..........................................................................................32
5. STUDY POPUL ATION
......................................................................................................32
5.1. I nclusion Criteria .....................................................................................................32
5.2. Exclu sion Criteria ....................................................................................................34
5.3.Lifesty le Considerations ..........................................................................................37
5.3.1. Contraception ..............................................................................................37
5.3.2. Meals and Dietary  Restriction ....................................................................37
5.3.3. Caffeine, Alcohol and Tobacco ................................ ................................ ..37
5.4. Screen Failures ........................................................................................................38
6. STUDY INTERVENTIO N
................................ ................................ ................................ ..38
6.1. Study  Intervention(s) Administered ........................................................................38

Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 56.1.1. Administration ............................................................................................39
6.2. Preparation/Handling/Storage/Accountability ........................................................41
6.2.1. Preparation and Dispensing ........................................................................43
6.3. Measures to 
Minimize Bias: Randomization and Blinding.....................................43
6.3.1. Allocation to Study Intervention ................................................................44
6.4. Study  Intervention Compliance ...............................................................................44
6.5. Concomitant Therapy ..............................................................................................45
6.6. Dose Modification ...................................................................................................46
6.7. I ntervention After the End of the Study ..................................................................48
7. DI SCONTINUATION O F STUDY 
INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................48
7.1. Discontinuation of Study  Intervention ....................................................................48
7.2. Participant Discontinuation/Withdrawal from the Study ........................................[ADDRESS_534558] to Follow -
up ....................................................................................................50
8. STUDY ASSESSMENTS AND PROCEDURES ...............................................................50
8.1. Efficacy  Assessments ..............................................................................................52
8.1.1. I maging Assessments ..................................................................................52
8.2. S afety Assessments .................................................................................................52
8.2.1. Phy sical Examinations ................................................................................52
8.2.2. Vital Signs ..................................................................................................52
8.2.3. Electrocardiograms
.....................................................................................53
8.2.4. C linical Safety  Laboratory  Assessments ....................................................53
8.2.5. Pregnancy  Testing ................................ ................................ ...................... 54
8.3. Adverse Events and Serious Adverse Events..........................................................54
8.3.1. Time Period and Frequency  for Collecting AE and SAE Information .......54
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety ...............................................55
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
...................55
8.3.2. Method of Detecting AEs and SAEs ..........................................................56
8.3.3. Follow -up of AEs and SAEs .......................................................................56
8.3.4. Regulatory
 Reporting Requirements for SAEs ................................ ........... 56
8.3.5. Exposure During Pregnancy  or Breastfeeding, and Occupational 
Exposure ................................ ................................ ................................ .......... 56

Talazoparib
Protocol C3441037Final Protocol Amendment 1, 22 June 2021
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Exposure During Pregnancy......................................................57
[IP_ADDRESS]. Exposure During Breastfeeding ................................................[IP_ADDRESS]. Occupational Exposure .............................................................59
8.3.6. Cardiovascular and Death Events...............................................................598.3.7. Disease-Related Events and/or Disease-Related Outcomes Not 
Qualifying as AEs or SAEs..............................................................................[ADDRESS_534559].............................................................59
[IP_ADDRESS]. Lack of Efficacy........................................................................59
8.3.9. Medical Device Deficiencies......................................................................59
[IP_ADDRESS]. Prompt Reporting of Device Deficiencies to Sponsor ..............59
8.3.10. Medication Errors .....................................................................................59
8.4. Treatment of Overdose............................................................................................608.5. Pharmacokinetics ....................................................................................................618.6. Pharmaco dynamics..................................................................................................62
8.7. Genetics................................................................................................................... 62
8.7.1. Specified Genetics ......................................................................................62
8.9. Immunogenicity Assessments .................................................................................62
8.10. Health Economics .................................................................................................62
9. STATISTICAL C ONSIDERATIONS ................................................................................62
9.1. Estimands and Statistical Hypotheses .....................................................................63
9.1.1. Statistical Hypothesis..................................................................................63
9.2. Sample Size Determination.....................................................................................639.3. Analysis Sets ...........................................................................................................649.4. Statistical Analyses .................................................................................................64
9.4.1. General Considerations...............................................................................649.4.2. Primary Endpoint(s)....................................................................................649.4.3. Secondary Endpoint(s)................................................................................65
[IP_ADDRESS]. Pharmacokinetic Analyses ........................................................[IP_ADDRESS]. Safety Analyses .........................................................................66CCI
CCI
Talazoparib
Protocol C3441037Final Protocol Amendment 1, 22 June 2021
PFIZER CONFIDENTIAL
Page 79.5. Interim Analyses .....................................................................................................66
9.6. Data Monitoring Committee or Other Independent Oversight Committee.............66
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ..........................................................................................................67
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ...............67
10.1.1. Regulatory and Ethical Considerations ....................................................67
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP.........................................................................67
10.1.2. Financial Disclosure .................................................................................6810.1.3. Informed Consent Process ........................................................................6810.1.4. Data Protection .........................................................................................6910.1.5. Dissemination of Clinical Study Data ......................................................6910.1.6. Data Qualit y Assurance ............................................................................71
10.1.7. Source Documents....................................................................................7210.1.8. Study and Site Start and Closure ..............................................................7210.1.9. Publication Policy.....................................................................................7310.1.10. Sponsor’s Qualified Medical Personnel .................................................74
10.2. Appendix 2: Clinical Laboratory Tests .................................................................7510.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting ......................................................................76
10.3.1. Definition of AE .......................................................................................7610.3.2. Definition of SAE.....................................................................................7710.3.3. Recording/Reporting and Follow-up of AEs and/or SAEs.......................7910.3.4. Reporting of SAEs....................................................................................82
10.4. Appendix 4: Contraceptive Guidance ...................................................................83
10.4.1. Male Participant Reproductive Inclusion Criteria ....................................8310.4.2. Female Participant Reproductive Inclusion Criteria.................................8310.4.3. Woman of Childbearing Potential ............................................................8410.4.4. Contraception Methods.............................................................................85
10.6. Appendix 6: Liver Safety: Suggested Actions and Follow-up Assessments ........88CCI
CCI
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 810.7. Appendix 7: ECG Findings of Potential Clinical Concern ...................................90
10.8. Appendix 8: Alternative Measures During Public Emergencies ..........................92
10.8.1. Eligibility ..................................................................................................92
10.8.2. Telehealth Visits .......................................................................................92
10.8.3. Alternative Facilities for Safet y Assessments ..........................................93
[IP_ADDRESS]. Laboratory  Testing ..................................................................93
[IP_ADDRESS]. I maging ....................................................................................93
[IP_ADDRESS]. Electrocardiograms
..................................................................93
10.8.4. Study  Intervention ....................................................................................93
10.8.5. Home Health Visits ...................................................................................94
10.8.6. Adverse Events and Serious Adverse Events ...........................................94
10.9. Appendix 9: L ist of L ong Half -Life Drugs with No Potential for Drug 
Interaction with Talazoparib ......................................................................................94
10.10. Appendix 10: Abbreviations ...............................................................................[ADDRESS_534560] OF FIGURES
Figure 1. Simulated PK and Pharmacod ynamics (Hemoglobin) Profiles After 
1 mg QD Talazoparib ...............................................................................29

Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 101.PROTOCOL SUMMARY 
1.1.Synopsis 
Short Title: A Phase [ADDRESS_534561] study for the proposed talazoparib soft gel capsule formulation in participants 
with advanced solid tumors
Rationale
In order to facilitate greater flexibility  in batch size production, a proposed talazoparib 
liquid -filled soft gel atin capsule ( hereafter referred as “ soft gel capsule ”)form ulation is 
currentl y being developed. The drug substance will be dissolved into a fill consisting of 
polyethylene gly col, gly cerol and tocophe rol.The fill will be encapsulated into a shell 
consisting of gelatin, sorbitol, gly cerol and pi[INVESTIGATOR_165639]. This study will be conducted to support 
the bridging of the current commercial capsule with the proposed talazoparib soft gel capsule
formulation , and to e xplore the potential food effect on the pharmacokinetics of the proposed 
talazoparib soft gel capsule formulati on.
Objectives, Estimands, and Endpoints
Objectives Endpoints
Primary: Primary: 
To establish the BE of the proposed talazoparib soft 
gelcapsule formulation to the current commercial 
formulation (Gen 3.1 talazoparib capsules) after 
multiple dosing under fast ing condition .
To estimate the effect of food on the PK of the 
proposed talazoparib soft gel capsule formulation 
after multiple dosing.Plasma AUC 24and C maxof talazoparib after 
multiple dosing under fasted conditions .
Plasma AUC 24and C maxof talazoparib after 
multiple dosing under fed condition.
Secondary: Secondary: 
To characterize th erelevant talazoparib plasma PK 
parameters for all treatments.
To evaluate the safety and tolerability of the 
proposed talazoparib soft gel capsule formulation.Plasma CL/F , Tmax, AUC last, and C trough of 
talazoparib after multiple dosing for all treatments.
Incidence of AEs characterized by [CONTACT_24975], severity 
(graded by [CONTACT_94979] 5.0), timing, 
seriousness and relationship to study treatment. 
Overall Design
This will be a Phase 1, open label, 2 -sequence, crossover study  to establish the BE of the 
current commercial formulation (Generation 3.1 talazoparib capsules) to the proposed 
talazoparib liquid -filled soft gelatin capsule (soft gel capsule) formulation after multiple 
dosing under fasting conditions in participants with advanced solid tumors. In addition, the 

Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June [ADDRESS_534562] evaluation 
phase .Initial number of 46participants is estimated based on 52% non-evaluable rate and 
might be adjusted during enrollment if non- evaluable rate changes.
When approximately 12 evaluable participants complete both Periods 1 and 2, initial 
assumptions (AUC 24variability and point estimate) for power/sample size calculation may be 
reassessed. Sample size may be increased; however the total number of participants to be 
enrolled in the study  may not exceed approximately  [ADDRESS_534563] on the PK of the proposed talazoparib soft gel capsule
formulation that will be included in the fixed sequence after the 2 BE assessment periods (for 
participants who can tolerate one high -fat/high -calorie meal) .Participants must have receive d 
[ADDRESS_534564] experienced renal function worsening to moderate/severe 
renal impairment during the study , or have completed the food effect assessment, will be 
rolled over to the maintenance phase which w
ill consist of repeating 28 day  cycles of 
treatment with the current commercial formulation.
Treatm ent Sequence Period 1 Period 2 Period 3
1 (n=2 3in total) B A C
2 (n=2 3in total) A B C
Treatment A: current commercial talazoparib formulation 1 mg once daily given under fasting condition 
(reference for BE evaluation)
Treatment B: the proposed talazoparib soft gel capsule formulation 1 mg once daily given under fasting 
condition (test for BE evaluation, reference for food effect eva luation)
Treatment C: the proposed talazoparib soft gel capsule formulation 1 mg once daily given with food (on the 
PK sampling day, high -fat/high -calorie meal will be administered in the clinical sites prior to the 
administration of the proposed talazopar ib soft gel capsule formulation; test for food effect evaluation)

Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 12Data Monitoring Committee or Other Independent Oversight Committee: No
This study  will not use a DMC .
Statistical Methods
Sample Size Estimation
It is estimated that 22 participants will be required to provide 90% power that the 90% CIfor 
the Test/Reference ratio of talazoparib AUC 24fallswithin the 80‑125% acceptance interval 
for bioequivalence. Additionally , with [ADDRESS_534565]/Reference 
ratio for C maxwill fall within 80% -125% is estimated to be 86%. These estimates arebased 
on the assumption that the true ratio between Test and Reference treatments for AUC 24and 
Cmaxis 1.[ADDRESS_534566].
Estimates of the adjusted mean differences (Test- Reference) and corresponding 90% CIs will 
be obtained from the model. The adjusted mean differences and 90% CIs for the differences 
will be exponent iated to provide estimates of the ratio of adjusted geometric means 
(Test/Reference) and 90% CI s for the ratios. Treatment A (commercial formulation given 
under fasting condition) will be the Reference treatment while Treatment B (the proposed 
talazoparib soft gel capsule formulation under fasting condition) will be Test treatment.
To ass ess food eff ect, natural log transformed AUC 24and C maxafter multiple dosing on the 
last day  of treatment B and C will be analy zed using a mixed effect model with sequence and 
treatment as fixed effects and participant within sequence as a random effect. Estimates of 
the adjusted mean differences (Test ‑Refere nce) and corresponding 90% CIs will be obtained 
from the model. The adjusted mean differences and 90% CI s for the differences will be 
exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) 
and 90% 
CIsfor the ratios. Treatment B (the proposed talazoparib soft gel capsule 
formulation under fasting condition) will be the Reference treatment while Treatment C (the 
proposed talazoparib soft gel capsule formulation given with high fat/high -calorie meal) will 
be the Test treatment. 
If initial design assumptions are reassessed during the trial, additional sensitivity  anal ysis of 
BE will be performed b y combining estimators from 2 stages using Cui , Hung, Wang 1999.1
The 90% CI will be constructed using combined weighted estimate and standard error from 
2stages1.

Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June [ADDRESS_534567]. Descriptive statistics will be used.

Talazoparib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 141.2.Schema 

Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 19PK Sampling Schedule on PK Visits
Visit Days Time Points Window of Acceptability
Period 1 Day 27 *
Period 2 Day 20*Predose PK Collection 24 ± 2 hours from dose on prior day and before the dosing time on the PK sampling day
Period 1 Day 28 **
Period 2 Day 21**
Period 3 Day 21**Predose PK Collection 24 ± 2 hours from dose on prior day and before the dosing time on the PK sampling day
Talazoparib Dose Within 10 min utesafter the predose PK sample collection
0.5 hours PK Collection ±3 minutes
0.75 hours PK Collection ±5 minutes
1 hours PK Collection ±6 minutes
1.5 hours PK Collection ±9 minutes
2 hours PK Collection ±12 minutes
4 hours PK Collection ±24 minutes
6 hours PK Collection ±36 minutes
8hours PK Collection ±48 minutes
24 hours PK Collection *** ±60 minutes and before the dosing time on the same day, ie ,Day 1 in the following period
*PK sampling visits can occur betw een Day 2 5to Day 29for period 1, and can occur between Day 18and Day 27for period 2 w hile continuing daily drug 
administration to accommodate scheduling convenience and compliance as described in the footnotes of the SoA. 
**PK sampling on Period 1 Day 28 and Period 2 Day 21 occur on the day simmediately after Period 1 Day 27 visit and Period 2Day 20 visit, respectively ; 
PK sampling on Period 3 Day 21 can occur betw een Day 19 and Day 28 while coninuitng daily drug administration to accommodate scheduling 
convenience and compliance as described in the footnotes of the SoA .
***[ADDRESS_534568] recent indication was approved for olapar ib on December 2019 by [CONTACT_423171] -mutated (gBRCAm ) metastatic pancreatic adenocarcinoma, as detected b y an FDA -
approved test, whose disease has not progressed on at least [ADDRESS_534569] -line platinum -
based chemotherapy regimen.2
Indications for maintenance therapy  in patients with ovarian, fallopi[INVESTIGATOR_8916], and peritoneal 
adenocarcinoma for patients with recurrent disease, BRCA -associated mutations, and with ≥2 
lines of chemotherap y were approved initially  in 2014 (olaparib, 2017,2018 ), and for other 
PARP inhibitor s in 2016 (rucaparib, 2018) and 2017 (niraparib, 2019 ).2,3,4,5
Olaparib is indicated for the following indications in ovarian, fallopi[INVESTIGATOR_8916] ,and primary  
peritoneal cancer: maintenance treatment of recurrent ovarian cancer and advanced gBRCA 
mutated ova rian cancer after [ADDRESS_534570] cancer in 2018 (olaparib), and 2018 (talazoparib).2,5
Talazoparib is highl ypotent at inducing single agent sy nthetic lethalit y of BRCA1 and 
BRCA2 deficient tumor cells in vitro . Consistent with its cy totoxic effects in tissue culture 
studies, talazoparib
demonstrated antitumor activity in xenograft tumor models. Potent tumor 
activity  was observed at an oral dail y dose 1 mg/kg/day .Complete suppression of growth of 
BRCA1 -deficient tumors (ie, MX1 model) was achiveved in a 3 -month study  when 
talazoparib wa s dosed at 0.165 mg/kg . These in vitro and in vivo activities suggest that 
talazoparib may  have clinical activity  in patients with BRCA mutated breast cancer.
In Study  PRP001 , a Phase 1, first in human, single -arm, open- label dose escalation study  of 
once daily talazoparib (BMN 673) in patients with advanced or recurrent solid tumors with 
DNA repair deficiencies, a total of 110 patients were treated with talazoparib at doses 
ranging from 0.025 to 1.1 mg/day .During the dose escalation phase of the study , 2of the 
6 patients enrolled in the talazoparib 1.1 mg/day  dose level experienced a dose limiting 
toxicity : one was Grade 4 thrombocy topenia, the other was Grade 3 thrombocy topenia 
requiring >5 days off study  treatment. Therefore, 1 mg/day  was considered the maximum 
tolerated dose and recommended Phase 2 dose. Between the dose escalation and dose 
expansion portions of the study , a total of 77 patients were treated with talazoparib at the 1 
mg/day  dose level in Study  PRP001 which was generall y well tolerated a nd warranted 
further evaluation in patients with solid tumors with DNA repair deficiencies. As a result, 
talazoparib has been dosed at 1 mg/day  in subsequent studies in patients with solid tumors, 
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June [ADDRESS_534571] cancer studies ABRAZO, E MBRACA, and currently  
ongoing investigator -initiated research trials.
The class of PARP inhibitors has demonstrated a risk for dose- dependent reversible 
myelosuppression and gastrointestinal toxicity , and these events were observed in studies 
where patient s received 1mg /day talazopi[INVESTIGATOR_423159] y.Study  drug -related TEAEs 
occurring in ≥ 20% of patients in the talazoparib 1 mg/day  population were anemia (45.8%), 
fatigue (36.1%), nausea (32.5%), neutropenia (21.9%), and alopecia (20.1%). Grade 3 or 4 
drug-related TEAEs occurring in ≥5% of patients were anemia (34.1%), neutropenia 
(13.9%), thrombocy topenia (10.6%), and platelet count decreased (5.4%). 
2.2.1. Clinical Overview
Talazoparib is currently  approved and in development for the treatment of a variet y of 
cancers. Approximately  [ADDRESS_534572] recent investigator’s brochure (30 September
2019).
The single dose PK of talazoparib have been evaluated in a total of 7clinical studies, of 
which 6 were conducted in cancer patients ( Studies PRP -001, PRP - 002, MDV3800 - 01,
MDV3800 -
03,MDV3800 -04,andMDV3800 -14) and 1 in healthy  subjects ( Study  673-103).
After administration of a single 1 mg dose of talazoparib capsules to can cer patients, the 
median Tmaxranged from 
1.0 to 2.0 hours across studies. The geometric mean Cmaxranged 
from 4.35 to 8.79 ng/mL and the geometric mean AUC infranged from 116 to 220 ng•hr/mL.
Talazoparib was eliminated slowly  with the geometric mean CL/F values ranging from 4.55 
to 7.71 L /hr and the mean t ½ranging from 62.4 to 98.1 hours, while the t ½of 62.4 hours 
might be an underestimate as the PK sampling time was onl y up to 168 hours postdose in the
corresponding stud y.The talazoparib geometric mean V z/F values estimated ranged from 447 
to 847 L , which is significantly  greater than total body  water (42 L), indicating that 
talazoparib extensively  distributes to peripheral tissues.
The PK of talazopar ib following multiple oral daily doses was evaluated in a total of 
6studies in patients with cancer ( Studies PRP -001, PRP- 002 , 673-201, 673-301, 
MDV3800 -
01,and MDV3800 -14), and Studies 673 -201 and 673-301 only included sparse 
sampling. Following repeated 1 mg QD dosing of talazoparib capsules in cancer patients, 
talazoparib was rapi[INVESTIGATOR_2478] y absorbed with a median T maxranging from approximately 1.0 to 2.0 
hours. The geometric mean C maxvalues ranged from 11.4 to 19.1 ng/mL  and the geometric 
mean AUC 24values r anged from 126 to 208 ng•hr/mL . The talazoparib geometric mean 
Ctrough values ranged from 2.99 to 4.95 ng/mL. The geometric mean CL /F ranged from 4.80 
to 5.53 L /hr, with a mean plasma t ½of 57.8 hours ( Study  PRP -001), which may  be an 
underestimate as the l ast PK sampling time was at 168 hours postdose.
Based on the multiple dosing data from Studies PRP -
001and PRP-002 and consistent with 
its observed t ½of 89.8 hours ( Study  MDV3800 -03), talazoparib plasma concentrations 
reached stead y state around 3 weeks after repeated daily  dosing. The median accumulation 
ratio ranged from 2.33 to 5.15 following repeated oral administration of 1 mg dose.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 24Thetalazoparib plasma exposure (AUC 24) and C maxincreased in a dose -proportional manner 
over the dose range of 0.025 to 2 mg QD.
2.3.Benefit/Risk Assessment
The doses of talazoparib in this protocol are supported by  [CONTACT_423172]. Talazoparib has shown anti-tumor activity  in 
patients with breast, ovarian, peritoneal and pancreatic cancers, as described in the 
background and talazoparib I nvestigator’s Brochure. Talazoparib is currently  approved for 
use in patients with metastatic breast cancer with germline BRCA mutations.
The expected AEs with talazoparib include m yelosuppression, gastrointestinal toxicity , 
fatigue, and alopecia. Hepatotoxicity , febrile neutropenia, and neutropenic sepsis are 
potential risks per the Investigator’s Brochure , Section 7 . T he activity  of talazoparib as 
monotherap y and in combination with other agents is being evaluated in multiple indications.
Based on the available safety  and efficacy  data, the overall benefit risk profile of talazoparib 
remains favorable.
More detailed inf ormation about the known and expected benefits and risks and reasonabl y 
expected AEs of talazoparib may  be found in the Investigator’s Brochure , which is the SRSD 
for this study .
2.3.1. Risk Assessment
Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for 
RiskMitigation Strategy
Study Intervention(s) talazoparib
Potential risks associated with 
talazoparib include the 
following: MDS ,AML and 
myelosuppresion. The potential risks are based 
on safety data summarized in 
product label and the 
investigator’s brochure for 
talazoparib. Eligibility criteria have been 
selected to ensure that only 
appropriate participants are 
included in the study (see 
Section 5 ).
Conduct safety assessment 
(eg,hematology) according to 
the SoA. 
Investigator can provide 
unplanned assessment  as 
clinically indicated.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June [ADDRESS_534573], ovarian, peritoneal and 
pancreatic cancers, as described in the background and talazoparib Investigator’s Brochure .
The benefit of talazopairb for individual pariticipants with s olid tumor smay include:
Potential clinical benefit of receiving talazo parib during stud y. 
Participant sin this study  will contribute to the process of developi[INVESTIGATOR_007] a new 
formulation for talazoparib.
Medical assessment (eg, phy sical exam s, ECG s
, labs, etc.) associated with study  
procedures 
and health care provider visits will be more frequent compared to standard 
of care.
2.3.3. Overall Benefit/Risk Conclusion
Taking into account the measures taken to minimize risk to participants participating in this 
study , the potential risks identified in association with talazoparib are justified by  [CONTACT_423173].
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 263.OBJECTIVES, ESTIMAND S, AND ENDPOINTS
Objectives Endpoints
Primary: Primary: 
To establish the BE of the proposed talazoparib soft gel
capsule formulation to the current commercial 
formulation (Gen 3.1 talazoparib capsules) after 
multiple dosing under fasting condition .
To estimate the effect of food on the PK of the 
proposed talazoparib soft gel capsule formulation after 
multiple dosing.Plasma AUC 24and C maxof talazoparib after multiple 
dosing under fasted condi tions.
Plasma AUC 24and C maxof talazoparib after multiple 
dosing under fed condition.
Secondary: Secondary: 
To characterize th etalazoparib plasma PK parameters 
for all treatments.
To evaluate the safety and tolerability of the proposed 
talazoparib soft gel capsule formulation.Plasma CL/F, T max, AUC last, and C trough of talazoparib 
after multiple dosing for all treatments.
Incidence of AEs characterized by [CONTACT_24975], severity 
(graded by [CONTACT_94979] 5.0), timing, 
seriousness and relationship to study treatment.
4.STUDY DESIGN
4.1.Overall Design
This will be a Phase 1, open label, 2 -sequence, crossover study  to establish the BE of the 
current commercial formulation (Generation 3.1 talazoparib capsules) to the proposed 
talazoparib soft gel capsule formulation after multiple dosing under fasting conditions in 
participants with advanced solid tumors, and to explore the potential food effect on the 
pharmacokinetics of the proposed talazoparib soft gel capsule formulation .The first [ADDRESS_534574] on the PK 
of the proposed talazoparib soft gel capsule formulation that will be included in the fixed 
sequence after the 2 BE assessment periods (for participants who can tolerate one 
high-fat/high -calorie meal) .Participants must have received [ADDRESS_534575] unstable renal function 
(>25% change in CLCR between 2visits which is considered clinically  significant by  [CONTACT_423174] a dose reduction), have experienced renal function worsening to 
moderate/severe renal impairment (CLCRdropped to <60 mL /min) during the study , or have 
completed the food effect assessment
, will be allowed to roll over to the maintenance phase
which will consist of repeating 28 day  cycles of treatment with the current commercial 
formulation .The maintenance phase consists of repeating 28 day  cycles of treatment with the 
current commercial formulation.
Participants will be randomly  assigned to 1 of the 2 sequences shown in Table 1.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 27Table 1. Treatment Sequences
Treatm ent 
SequencePeriod 1 Period 2 Period 3
1 (n= 2 3in total) B A C
2 (n= 2 3in total) A B C
Treatment A: current commercial talazoparib formulation 1 mg once daily given under fasting condition 
(reference for BE evaluation)
Treatment B: the proposed talazoparib soft gel capsule formulation 1 mg once daily given under fasting 
condition (test for BE evaluation, reference for food effect evaluation)
Treatment C: the proposed talazoparib soft gel capsule formulation 1 mg once daily given with food (on the 
PK samplin g day, high -fat/high -calorie meal will be administered in the clinical sites prior to the 
administration of the proposed talazoparib soft gel capsule formulation; test for food effect evaluation)
Approximately  46participants ( 23per sequence) will be enrolled in tothe study intervention
to ensure at least [ADDRESS_534576] evaluation phase .Initial number of 46participants is estimated based on 52% 
non-evaluable rate and might be adjusted during enrollment if non-evaluable rate changes.
When approximately  12 evaluable participants complete both Periods 1 and 2, assumptions 
(AUC 24variability  and point estimate) for power/sample size calculation may  be reassessed
.
Sample size may  be increased ; however, the total number of participants to be enrolled in the 
study  may  not exceed approximately 88 participants.
Participants will be randomized 1:[ADDRESS_534577] 2 periods and can tolerate one 
high-fat/high- calorie meal will receive treatment C in period [ADDRESS_534578] had less than 21 consecutive day s of continuous QD dosing of IP (regardless of 
formulation) on the last day  of a treatment period will be considered non-completers of that 
treatment period (Period X). PK assessment will not be performed for non -completers of a 
treatment periods, but other scheduled activi ties will be performed per the SoA.After 
completion of Period X, instead of moving on to the next treatment, the same treatment in 
Period X will be repeated until participants have received at least [ADDRESS_534579] day  of the treatment period (ie, considered as completers).
4.2.Scientific Rationale for Study Design
Talazoparib is clastogenic and therefore it is unacceptable to enroll healthy participants for 
this study . All clinical studies administering talazoparib should be conducted in cancer 
patients for whom there is potential benefit to offset this risk. Cancer patients who will likely  
benefit from talazoparib treatment and have good disease control will be recruited to 
minimize dropouts through progres sion of disease because of the long duration of treatment
(at least 70days).The selected participant population willinclude patients with advanced 
solid tumors that are not amenable for treatment with curative intent who may  benefit from 
treatment with talazoparib.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 28Due to the selected participant population, a single -dose study  is not feasible as the long 
elimination half -life ( t½, 89.9±57.6 hours) of talazoparib would require too long a washout 
duration with no treatment to be ethical in a cancer patie nt population setting. Due to high 
PK variability  of talazoparib in cancer patients, (total variability  of 47 -62% for C maxand 
32%-42% for AUC [ PRP-002 and MDV380 0-04 with N>18], single dose studies ), a parallel 
study  design 
would require a large sample size (>100 participants per arm) and therefore 
would not be feasible. Collectively , inherent properties of talazoparib limit the acceptable 
BA/BE assessment options to a multiple -
dose crossover design in cancer patients. In order to
achieve 90 % power that the 90% CIfor the Test/Reference ratio of talazoparib C maxfall 
within the 80
‑125%, a full replicate design (TRTR, RTRT) with 40 evaluable participants 
would be required. Due to the treatment length of this design (at least 84 day s), the non-
evaluable rate was estimated to be ~65% and approximately 114participants need to be 
enrolled, rendering the implementation of this design non -feasible. In addition, C maxis not 
considered a main driver for the efficacy  and safety  events of talazopari b as illustrated below. 
If the C maxof the proposed formulation is lower than that of the current commercial 
formulation, it is not expected to have an impact on efficacy . In the preclinical studies, in 
MX1 tumors xenograft model, dosing talazoparib at 0.166 mg/kg BID schedule showed a 
better anti -tumor effect profile compared to dosing talazoparib at 0.33 mg/kg QD schedule.
This suggests C maxis not the driver for efficacy .This study  result led to the registrational 
Phase 3 study  (Study  C3441009; EMBRACA ) being conducted with talazoparib taken 
without regard to food intake, as food had no effect on the AUC even though it reduced 
talazoparib C maxby 46%. Consistently , in the USPI [INVESTIGATOR_423160]. 
The lack of impact of higher C maxon safet y was evaluated using ER modeling.
Myelosuppression- related AEs are the main side effects of talazoparib treatment and Anemia 
was reported for 49.2% of patients ( Module 2.7.4 NDA 211651 seq 001). Thus, Anemia was 
selected as a representative safet y endpoint for ER modeling to evaluate the impact of C max
increase on the safet y profile of talazoparib. Simulations were conducted to compare the 
projected PK profile based on the assumed 
ratio between the two formulations (10% higher
Cmax for the proposed formulation) and the time course of A nemia ( Figure 1).Patient ID 1 
represented the population ty pi[INVESTIGATOR_423161]; Pa tients ID2 had 10% higher C max
and same AUC 24compared to Patient I D1. As shown in Figure 1, 
limited increase of C max
would not have significant impact on the safet y profile of talazoparib (Anemia) when AUC 
remains the same.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 29Figure 1.Simulated PK and P harmacodynamics (Hemoglobin) Profiles After [ADDRESS_534580] crossover study  power ed to show 90% CI for the 
Test/Reference ratio of talazoparib AUC 24within the 80
‑125% acceptance interval for BE
was selected.
In order t o assess the steady  state PK of talazoparib to demonstrate BE, lengthy  continuous 
treatment with talazoparib at [ADDRESS_534581] adequate treatment durations prior to PK assessment for stead y 
state BE evaluation, simulations were conducted using the final popPK model submitted in 
the original NDA 211651 (PMAR -EQDD- C344a -DP4-840) .Using the proposed treatment 
duration for each period, simulation s were performed for fixed sequence with the second 
administered formulation having known bioavailability  (F1) changes (10% or 5% increase or 
10% or 5% decrease in F1 relative to the first administered formulation). Population ty pi[INVESTIGATOR_423162] 5 percen tile CL  were used to represent ty pi[INVESTIGATOR_423163]  (slower elimination and longer half -life). In the simulation, formulation 1 was 
administered from Day  1 to Day  28, and formulation 2 was administered from Day  29 to Day  
56. PK parameters obtained on Day  14 of Period 2 (ie, Day 42) for the second formulation 
were compared to those obtained on Day [ADDRESS_534582] on bioavailability .In addition, the second 
formulation had extended dosing to Day  28 for Period 
2 (ie, Day  56) in the simulation to 
further demonstrate whether the stead y state for the second formulation was achieved on Day  
14 of Period 2 by [CONTACT_423175]  14 and Day  28 of Period 2 respectivel y.
Table 2exhibits the simulation results. When the formulation with 10% higher F1 was 
administered in Period 3, the ratio of AUC 24obtained on Day  14 in Period 2 (Day  42) vs 
AUC 24obtained on Day 28 of Period 1 (Day  28) exhibited 9.9% and 9.8% increase when 
population ty pi[INVESTIGATOR_423164] 5 pe rcentile CL  were used in the simulation, 
respectivel y.AUC 24ratio was similar between Day 42 and Day 56, which indicates that no 
meaningful improvement in accuracy  is achieved with additional 14 day s of treatment in 
Period 
2.The same results were observe d for the simulated formulation with 5% higher or 
5% lower or 10% lower F1 case scenarios. These simulation results suggest that following 
28-day treatment of the first formulation, a minimum of 14- day treatment duration for the 
following periods is needed for stead y state BE and food effect evaluation , and therefore 
21-day treatment for period [ADDRESS_534583] clinically  recommended dose strength of talazoparib is 
1 mg taken as a single oral daily  dose in the approved indication (deleterious or suspected 
deleterious gBRCAm HER2- negative locall y advanced or metastatic breast cancer). 
Therefore, the highest approved dose streng th, [ADDRESS_534584] completed the study  if he/she has completed all phases of 
the study , including the End of Study  visit.
The end of the stud y is defined as the date of the l ast scheduled procedure shown in the SoA
for the last participant in the trial globall y after collection of the final data point for primary  
and secondary  study  objectives.
5.STUDY POPULATION
This study  can fulfill its objectives only if appropriate participants are enrolled. The 
following eligibility  criteria are designed to select participants for whom participation in the 
study  is considered appropriate. All relevant medical and nonmedical conditions should be 
taken into consideration when deciding whether a particular participant is suitable for this 
protocol. 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, arenot permitted.
5.1. Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria appl y:
Age and Sex:
1. Male or female participants between the ages of 18 (or the minimum coun tryspecific age 
of consent if >18) and 70 y ears, inclusive, at Visit 1 (Screen 1).
Type of Participant and Disease Characteristics:
2.Histological diagnosis of recurrent, locall y advanced or metastatic solid tumor that is not 
amenable for treatment with cur ative intent. 
a.Solid tumors with known or likely  pathogenic germline or somatic tumor gene defect (eg, 
one or more BRCA1 or BRCA2 gene defect except for ovarian cancer) that would benefit 
from PARPi [INVESTIGATOR_423165]. Gene mutation determined by  [CONTACT_423176] a test of either germline or tumor DNA which was performed in a 
CAP/CLIA certified (or comparable local or regional certified) laboratory.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June [ADDRESS_534585] 1 prior SOC regimen, if it exists, as appropriate for the respective tumor 
type unless deemed unsuitable or declined these therapi[INVESTIGATOR_014]; ovarian cancer participants 
must have at least [ADDRESS_534586] 1 l ineof 
platinum -based therap y.Participants (except for those with ovarian cancer) must not have 
had disease progression within 6 months of initiation of platinum containing regimen;
Participants with ovari an cancer must not have progressed during or within [ADDRESS_534587] recent platinum -based chemotherap y;
Participants with ovarian cancer previously  treated with ≤[ADDRESS_534588] dose of platinum- based chemotherap y, also termed “platinum -
resistant recurrent disease”
Participants with ovarian cancer previously  treated with >2 prior cy totoxic 
chemotherap y regimens, ie, platinum sensitive recurr ent disease is allowed;
Any treatment regimen that began with cy totoxic chemotherap y and continued with 
another regimen for maintenance therap y following best response to initial cy totoxic 
regimen will count as one line of prior therap y.
c.Participants with NSCL C harboring B -Raf proto- oncogene (BRAF) v600 mutations,
ALK and c -ros oncogene 1 (ROS1) translocation/rearrangements, or epi[INVESTIGATOR_8199] (EGFR) mutation smust have received the appropriate targeted therap y as 
approved by [CONTACT_423177] .
3.ECOG performance score of 0 -
1.
4.
Adequate bone marrow function, as defined as:
ANC ≥1500 cells/mm3
Platelets ≥100,000 cells/mm3 
Hemoglobin ≥10.0 g/dL 
5.Adequate renal function, as defined as:
A CL CR≥60 mL /min by [CONTACT_3158] -Gault formula or as: CL CR={[(140 –age) × 
weight)]/(72 × SCR)} × 0.85 (if female), where CLCR is measured in mL/min, age is 
expressed in y ears, weight in kilograms, and SCR in mg/dL ;Other method sfor 
calculating CLCRcan be used as long as the same method is used for the entire study ;
No documented CL CR <60 mL /min and no change in CL CR >25% in the past 4 weeks.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 346.Adequate hepatic function, as defined as:
AST and ALT ≤2.5 × ULN; if liver function abnormalities are due to hepatic metasta sis, 
then AST and ALT ≤5 × ULN; 
Total bilirubin ≤1.5 × ULN ( ≤3 ×ULN for Gilbert ’s syndrome); 
7.Life expectancy  of at least [ADDRESS_534589] yle considerations, and other study  procedures.
Informed Consent:
10.Capable of giving signed informed consent as described in Appendix 1 , which includes 
compliance with the requirements and restrictions listed in the I CD and in this protocol. 
5.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1. For ovarian participants: Non-epi[INVESTIGATOR_423166] (ie, borderline tumors) or mucinous tumors.
2. Toxicities from previous anti- cancer therapi[INVESTIGATOR_423167] Grade 
2, except for alopecia, sensory  neuropathies ≤Grade 2, or other Grade ≤2 AEs not 
constituting a safety  risk, based on investigator’s judgment, are acceptable.
3.Diagnosed with MDS or AML .
4.Active infection requiring s ystemic therapy  within 2 weeks of enrollment.
5.
Transfusions or hematopoietic growth factors within 2 w eeks of enrollment.
6.Any major surgery  within 4 weeks of enrollment.
7.Any condition in which active bleeding or pathological conditions may  carry  a high risk 
of bleeding (eg ,known bleeding disorder, coagulopathy  or tumor involvement with major 
vessels). 
8.Known or suspected brain metastasis or active leptomeningeal disease undergoing or 
requiring treatment. Asymptomatic brain metastases currently  not undergoing treatment 
are allowed.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June [ADDRESS_534590] compression is allowed if definitive treatment was provided and participant 
has stable disease 4 weeks prior to randomization.
10.In the opi[INVESTIGATOR_871], an y clinically  significant gastrointestinal disorder 
affecting absorption (eg, malabsorption sy ndrome, uncontrolled inflammatory  bowel 
disease, PUD, requires hyperalimentation, or prior surgical procedures effecting 
absorption.
11.Inability  to swallow capsules or any  known h ypersensitivity  to Talzenna™(talazoparib) 
or an y of the product components.
12.Clinically  significant cardiovascular disease:
Myocardial infarction or sy mptomatic cardiac ischemia within 6 months of 
randomization;
[LOCATION_001] Heart Association Class III or IV congestive heart failure;
History  of clinically  significant ventricular arrhy thmias (history  of sustained ventricular 
tachycardia, ventricular fibrillation, Torsades de Pointes) within 1 y ear prior to 
randomization.
History  of Mobitz II second degree or third degree heart block unless a permanent 
pacemaker is present.
Hypotension: s ystolic blood pressure <80 mm Hg at screening;
Brad ycardia: HR of <45 beats per minute at screening on electrocardiogram;
Uncontrolled h ypertension: systolic blood pressure >170 mm Hg or diastolic >105 mm 
Hg at screening; rescreening is allowed after adequate blood pressure control is achieved.
13.Women o f childbearing potential who are pregnant, breast -feeding or plan to conceive 
during stud y participation.
14.Women of childbearing potential who are unwilling or unable to use highly  effective 
methods of contraception as appropriate as outlined in this protoc ol for the duration of the 
study  and for [ADDRESS_534591] dose of IP.
15. Fertile male participants with female partners of reproductive potential or pregnant 
partners, unwilling to use a condom (even after vasectomy ) during treatment and for at 
least [ADDRESS_534592] infection, are 
allowed.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 3617.Other medical or psy chiatric condition including recent (within the past year) or active 
suicidal ideation/behavior or laboratory  abnormality  that may  increase the risk of study  
participation or, in the investigat or’s judgment, make the participant inappropriate for the 
study .
Prior/Concomitant Therapy:
18.Prior anti -cancer therap y within 2 weeks or 5 half -lives prior to randomization 
(whichever is longer) .Prior anti -cancer treatments with 5 half -lives longer than 30 day s 
and no evidence of drug -drug interaction (DDI) with talazoparib require a 30- day 
washout period
. See Section 10.9 Appendix 9for more details on DDI potential.
19.Current or anticipated use of P -gp inhibitors, BCRP inhibitors, and P -gp inducers within 
2 week s or 5 half-lives pr ior to randomization (whichever is longer) . See Section 6.5 for 
more details.
20.Prior radiation within 2 weeks of randomization. Prior palliative radiot herapy  to 
metastatic lesions(s) is permitted, provided it has been completed at least 2 day s prior to 
enrollment and no clinically  significant toxicities are expected (eg, mucositis, 
esophagitis).
Prior/Concurrent Clinical Study Experience:
21. Previous admini stration with an investigational drug within 30 days (or as determined by  
[CONTACT_19970]) or 5 half -lives prior to randomization (whichever is longer). Prior 
treatments with 5 half -lives longer than 30 day s and no evidence of DDI with talazoparib
require a 30 -day washout period.
Diagnostic Assessments:
22. QTc interval >470 msec. If the baseline uncorrected QT interval is >470 msec, this 
interval should be rate corrected using the Fridericia method and the resulting QTcF 
should be used for decision making and reporting. If QTc exceeds 470 msec, or QRS 
exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 
QTc or QRS values should be used to determine the participant’s eligibility. Computer 
interpreted ECGs should be overread by a phy sician experienced in reading ECGs before 
excluding participants.
Other Exclusions:
23.Investigator site staff or [COMPANY_007] employ ees directl y involved in the conduct of the study , 
site staff otherwise supervised by  [CONTACT_093], and their respectiv e family  members. 
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 375.3.Lifestyle Considerations
5.3.1. Contraception
The investigator or his or her designee, in consultation with the participant, will confirm that 
the participant has selected an appropriate method of contraception for the individual 
participant an d his or her partner(s) from the permitted list of contraception methods (see 
Appendix 4 Section 10.4.4 ) and will confirm that the participant has been instructed in its 
consistent and correct use. At time points indicated in the SoA, the investigator or designee 
will inform the participant of the need to use highly  effective contraception consistently  and 
correctly  and document the conversation and the participant’s affirmation in the participant’s 
chart (participants need to affirm their consistent and correct use of at least 1 of the selected 
methods 
of contraception). In addition, the investigator or designee will instruct the 
participant to call immediately  if the selected contraception method is discontinued or if 
pregnancy  is known or suspected in the participant or partner.
5.3.2. Meals and Dietary Restr iction
Bioequivalence and Food -effect Phase
On non- site visit day s, in the first [ADDRESS_534593] abstain from all food and drink 
(except water) at least [ADDRESS_534594], cottage cheese (90 g), 
buffalo milk (8 oz), an apple. (avocado and nuts 
can be substitutes)
50% of calories are derived from fat. Substitutions can be made to this meal, if the content, volume, and 
viscosity are maintained.
Safety  assessments should be reviewed prior to starting the next period of IP treatment. On 
Period 1 Day  1 (treatment sequence 2) or Period 2 Day 1 (treatment se quence 1), participants 
should be observed after dosing for an y events over the first 2 hours.
Guidance on missed doses and IP administered outside of the allowed window:
If vomiting occurs within 2 hours after drug administration, it will be considered as a 
missed dose. Participants should not make up vomited doses; dosing should resume 
on the next calendar day unless otherwise instructed.
Ifparticipants have had less than 21 consecutive day s of continuous QD dosing of IP 
(regardless of formulation) on th e last day  of a treatment period , they  will be 
considered non -
completers of that treatment period (Period X) . Otherwise the 
treatment needs to be extended within the allowed window or repeated for 21 day s 
(
-2/+7). PK assessment will not be performed for non-completers of a treatment 
period
, but other scheduled activities forD28 visit (period 1) or Day 21 visit (period 2 
and 3) will be performed per theSoA and new bottles of I P (same treatment as Period 
X)will be dispensed on D28 or D21 visit instead of Day  1. After the completion of 
Period X, 
instead of moving on to the next treatment, the same treatment in Period X 
will be repeated for 21 day s (-2/+7 day s).In this situation, where Period X gets 
repeated to ensure 2
1continuous days of dosing prior to PK assessment, the repeated 
period will get noted as Period Xa, and then if repeated a second time as Period Xb.
Please note the visit window sshown in the SoA ( -2/+2 day s for period 1 and -2/+7 
days for period 2 and 3) allow the treatment to be extended tomeet 21 (-2/+7)
continuous day s instead of repeating a period.
Participants must complete a given treatment period before they  can enter the next 
scheduled period.
If the participant has repeated a period twice due to a missed dose (original plus 2 
repeat periods, a total of 3 for the same period), the participant should discontinue the 
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 41BE/food effect Phase and roll over to the Maintenance Cy cle Phase schedule ( SoA).
The s ponsor reserves the right for taking participants off treatment due to compliance 
issue.
On the visit day s with PK assessment, participants will take I P at the site 
approximately  24 hours after the previous dose (ie, nominal time). Drug 
administration outside of ±2 hours of nominal time will be recorded as a protocol 
deviation. If drug administration occurs >28 hours from the previous dose (ie, >4 
hours after nominal time) or <20 hours from the previous dose (ie, <4 hours before 
nominal time), PK assessment will not be performed on that day and the participant 
will need to take at least 2 more daily  doses at the nominal time before performing the 
scheduled activities; as long as the visit occurs within (+4 day ) window of the 
original schedule .
If a participant forgets his daily  dose of I P at the time he/she ty pi[INVESTIGATOR_1306] y takes it, but 
remembers it later on the same day , the dose may  be taken on that day .As long as the 
delay ed dosing occurs at least [ADDRESS_534595] 2 days before the PK sampling visit.
Any dose that is missed (not taken on the same day  of the intended time) should be 
skipped and should not be made up on the followin g day .
In order to standardize the conditions on PK sampling day s, all participants will be required 
to refrain from ly ing down (except when required for BP, pulse rate, and ECG 
measurements) during the first [ADDRESS_534596] experienced renal function 
reduction to moderate/severe renal impairment during the stud y, or have com pleted the food 
effect assessment will roll over to the maintenance phase which will consist of repeating [ADDRESS_534597] dose fro m the BE and/or Food Effect 
Phase, whichever is later, with the commercial formulation. There are no specific dosing 
restrictions during the maintenance phase. IP may be taken with or without food.
During BE, food -effect, and maintenance phase of the study , participants will be instructed to 
self-administer their IP according to the provided administration instructions, store the I P at 
home at 20°C to 25°C (68°F to 77°F), return all unused IP/bottles to the site, and record 
study -specific details and any  deviations from instructions in a diary  provided for the study .
6.2.Preparation/Handling/Storage/Accountability
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  interventions received and an y 
discrepancies are reported and resolved before use of the study  intervention. 
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 422.Talazoparib is considered a cy totoxic and clastogenic agent; precautions regarding 
appropriate secure storage and handling must be used by  [CONTACT_129000], 
including personal protective clothing, disposable gloves, and equipment. Participants 
should be advised that oral anticancer agents (ie, talazoparib) are toxic substances and 
that other caregivers should alway s use gloves when handling the capsules.
3.Only  participants enrolled in the study  may  receive I P and onl y authorized site staff 
may suppl y or administer study intervention. All IP must be stored in a secure, 
environmentally  controlled, and monitored (manual or automated recording) area in 
accordance with the labeled storage conditions with access limited to the investigator 
and authorized site staff. At a minimum, daily  minimum and maximum temperatures 
for all site storage locations must be documented and available upon request. Data for 
nonworking day s mu st indicate the minimum and maximum temperatures since 
previously  documented for all site storage locations upon return to business.
4.Any excursions from the IP label storage conditions should be reported to [COMPANY_007] upon 
discovery  along with an y actions take n.The site should actively  pursue options for 
returning the IP to the storage conditions described in the labeling, as soon as 
possible. Once an excursion is identified, the I P must be quarantined and not used 
until [COMPANY_007] provides permission to use the I P.Specific details regarding the definition 
of an excursion and information the site should report for each excursion will be 
provided to the site in the I P manual.
5.Any storage conditions stated in the SRSD will be superseded by  [CONTACT_423178].
6.IP should be stored in their original containers.
7.Site staff will instruct participants on the proper storage requirements for take -home 
IP.
8. The following are the BA/BE retain requirements:
Stored by  [CONTACT_382815]
Stored under conditions consistent with product labeling
Stored in an area segregated from the area where testing is conducted 
Stored with access limited to authorized personnel
Minimum of 4 (30 count bottles), per lot of the test article and reference standard
The subject dosing and retention sample containers must be identical in 
formulation, manufactured lot, and packaging and labeling presentation.
For non -US sites, there may  be local country  regulations (eg, import license 
restrictions of subject dosing containers only) which prevent distribution of the 
retention sample containers; they  may  be stored at a 3rd part y vendor location 
contracted b y test site.
Each re serve sample shall be retained at the investigator site for a period of at 
least [ADDRESS_534598] 5 years following the date of completion of the bioavailability  
study  in which the sample from which the reserve sample was used.
9.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for IP accountability , reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records), such as the IPAL or sponsor
approved equivalent. All IP will be accounted for using a IP accountabilit y 
form/record. All IP that is taken home by  [CONTACT_2299], both used and unused, must 
be returned to the investigator b y the participant. Returned IP must not be redispensed 
to the participants. to the participants.
10.Further guidance and information for the final disposition of unused study  
interventions are provided in the I P manual. All destruction must be adequately  
documented. If destruct ion is authorized to take place at the investigator site, the 
investigator must ensure that the materials are destroy ed in compliance with 
applicable environmental regulations, institutional policy , and any  special instructions 
provided b y [COMPANY_007].
Upon ide ntification of a product complaint, notify the sponsor within 1 business day  of 
discovery as described in the I P Manual.
6.2.1. Preparation and Dispensing
The I P will be dispensed using an IRT drug management sy stem at each visit. A qualified 
staff member will di spense the I P via unique container numbers in the bottles provided, in 
quantities appropriate for the study  visit schedule. The participant/caregiver should be 
instructed to maintain the I P in the bottle provided throughout the course of dosing and return 
the bottle to the site at the next study  visit.
See the IP manual for instructions on how to prepare the IP for administration. IP should be 
prepared and dispensed by  [CONTACT_36534] y qualified and experienced member of the stud y 
staff (eg, ph ysician, nurs e, phy sician’s assistant, nurse practitioner, pharmacy  
assistant/technician, or pharmacist) as allowed b y local, state, and institutional guidance.
Only  qualified personnel who are familiar with procedures that minimize undue exposure to 
themselves and to the environment should undertake the preparation, handling, and safe 
disposal of PARP inhibitor agents.
6.3.Measures to Minimize Bias: Randomization and Blinding
The investigator’s knowledge of the treatment should not influence the decision to enroll a 
partic ular participant or affect the order in which participants are enrolled.
Participant numbers will be assigned as participants are screened for the study .Investigative 
sites will utilize I RT to assign randomization numbers and in accordance with the 
random ization numbers, the participant will receive the study  treatment regimen.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 446.3.1. Allocation to Study Intervention
Allocation of participants to treatment groups will proceed through the use of an IRT /IWR 
system. The site personnel (study  coordinator or specified designee) will be required to enter 
or select information including but not limited to the user’s ID and password, the protocol 
number, and the participant number. The site personnel will then be provided with a 
treatment assignment, randomization number, and DU or container number when stud y 
intervention is being supplied via the I RT s ystem. The I RT sy stem will provide a 
confirmation report containing the participant number, randomization number, and DU or 
container number assigned. The confirmation repor t must be stored in the site’s files. 
Study  intervention will be dispensed at the study  visits summarized in the SoA. 
Returned study  intervention must not be redispensed to the participants.
The study specific IRT reference manual and IP manual will provide the contact [CONTACT_19974] s ystem.
This will be an open label study ; however, the specific study  intervention dispensed to the 
participant will be assigned using an IRT. The site will contact [CONTACT_423179]. The site will record the study  
intervention assignment on the applicable CRF, if required. Potential bias will be reduced by  
[CONTACT_286919]: cent ral randomization, competitive enrollment.
The investigator’s knowledge of the treatment should not influence the decision to enroll a 
particular participant or affect the order in which participants are enrolled.
IP will be dispensed at the study  visits summarized in the SoA . 
Returned IP must not be re -dispensed to the participants.
The study specific IRT reference manual and IP manual will provide the contact [CONTACT_19974] s ystem.
6.4.Study Inter vention Compliance
Intervention compliance will be assessed at each visit. Compliance will be assessed b y 
counting returned capsules. For home IP self-administration, a diary  will be provided to the 
participant to aid in compliance with the dosing instruct ions. Participants should be 
instructed by  [CONTACT_423180] -time. The site should review 
participant s’ eDiary  IP compliance on add and 1 day  before the site visit day  to check for 
missed doses/out of window dosing and follow the guidance on missed doses and I P 
administered outside of the allowed window. Data entered in the diary  by [CONTACT_423181]/prior to dispensing additional IP. D eviation(s) from the prescribed dosage regimen 
should be recorded in the CRF .
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June [ADDRESS_534599] phase 
of this study .
During the Maintenance Phase, compliance is defined as 80% of the total doses for each 
cycle.See Section 8.3.10 for Medication Errors.
6.5.Concomitant Therapy
The following concomitant medications are prohibited during the stud y:
P-gp inhibitors: amiodarone, carvedilol, clarithromy cin, cobicistat, dronedaro ne, 
erythromy cin, glecaprevir/pi[INVESTIGATOR_187761], indinavir, itraconazole, ketoconazole, lapatinib, 
lopi[INVESTIGATOR_054], propafenone, quinidine, ranolazine, ritonavir, saquinavir, 
sofosbuvir/velpatasvir/voxilaprevir, telaprevir, tipranavir, valspodar, and verapamil, 
atorv astatin, azithromy cin, conivaptan, curcumin, cy closporine, diltiazem, diosmin, 
eliglustat, elacridar, eltrombopag, felodipi[INVESTIGATOR_050], flibanserin, fluvoxamine, pi[INVESTIGATOR_5329], 
quercetin, and schisandra chinensis extract.
P-gp inducers : avasimibe, carbamazepi[INVESTIGATOR_050], phen ytoin, rifampin, and St. John’s Wort.
BCRP inhibitors: curcumin, cy closporine, elacridar, and eltrombopag. 
Alternative therapi[INVESTIGATOR_4576]. If usage of any of the above 
treatment is deemed medically  necessary , consultation and ag reement with the sponsor is 
required prior to treatment initiation as appropriate dose modification of IP may  be needed.
Please refer to FDA website:
(https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInte
ractionsLabeling/ucm093664.htm#table5- 2 ) and University  of Washington Drug -Drug 
Interaction database (https://www.druginteractioninfo.org/) for DDI potential with P -gp and 
BCRP and contact [CONTACT_423182].
Concomitant use of an y systemic anti -cancer therapy  for disease under study  is not allowed 
during stud y participation.
Hormonal contraceptives that meet the requirements of this study  are allowed to be used in 
participants who are WOCBP (see Appendix 4 ).
All concomitant treatments taken during the study  must be recorded with indication, daily  
dose, unit and frequency , and start and stop dates of administration. All participants will be 
questioned about concomitant treatment at each clinic visit.
Treatments taken within [ADDRESS_534600] a 
formulation change. Dose reductions will be in increments of 0.25 mg/ dose, therefore, 
participant may  need to self -administer more than 1 capsule for the reduced dose which will 
be supplied as 0.25 mg capsules (eg, 0.75 mg = 3 capsules dail y, 0.50 mg = 2 capsules dail y, 
0.25 mg = 1 capsule daily) with 30 capsules per bottle. Treatment with I P should be 
discontinued if more than three dose reductions are required. 
Table 4. Dose Reduction Levels for Adverse Reactions
Dose Level Dose
Recommended starting dose 1 mg (one [ADDRESS_534601] dose reduction 0.75 mg (three 0.25 mg commercial formulation 
capsules) once daily
Second dose reduction 0.50mg (two 0.25 mg commercial formulation 
capsules) once daily
Third dose reduction 0.25 mg (one 0.25 mg commercial formulation 
capsule) once daily
After dose reduction, re -escalation is not allowed. Treatment -emergent hematological and 
non-hematological events will be managed b y the following dose modifications.
Table 5. Dose Modification and Management Due to Adverse Reactions
Toxicity Managem ent of Adverse Events 
Grade 1 or 2
Selected 
hematologic and 
nonhematologic 
grade 3 or 4 eventsNo requirement for dose interruption or dose reduction.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 47Table 5. Dose Modification and Management Due to Adverse Reactions
Toxicity Managem ent of Adverse Events 
Anemia 
(hemoglobin <8.0 
g/dL)Hold talazoparib and monitor weekly until hemoglobin returns to baseline (day 1) 
grade or better. Impleme nt supportive care per local guidelines.
Talazoparib may be reduced by 1 dose level per Table4.
If anemia persists for >[ADDRESS_534602] for evaluation, including assessment for 
possible MDS/AML.
Neutropen ia 
(ANC <1000/µL)Hold talazoparib and monitor weekly until ANC ≥1500/µL. Implem ent supportive 
care per local guidelines. Reduce talazoparib by 1 dose level per Table 4.
If neutropenia persists for >4 weeks without recovery to ≥1500/µL, discontinue 
talazoparib and refer to a hematologist for evaluation, including assessment for 
possible MDS/AML.
Thrombocytopenia 
(platelets 
<50,000/µL)Hold talazoparib until platelets ≥ 50,000/µL. Implem ent supportive care per local 
guidelines. Reduce talazoparib by 1 dose level per Table4.
If thrombocytopenia persis ts for >4 weeks without recovery to ≥50,000/µL, 
discontinue talazoparib and refer to a hematologist for evaluation, including 
assessment for possible MDS/AML.
Nonhematologic 
laboratory grade 
≥3 events except 
abnormal liver 
tests Hold talazoparib as follows: 
For clinically significant grade 3 laboratory abnormalities talazoparib may be 
held. Resume talazoparib at the same dose or reduce by 1 dose level per 
Table 4when the laboratory abnormality resolves to grade ≤2(baseline grade 
for creatinine increases). 
For grade 4 laboratory abnormalities, hold talazoparib. Resume talazoparib 
when the laboratory abnormality resolves to grade ≤2(baseline gra de for 
creatinine increases) at a [ADDRESS_534603] be discontinued if a grade 4 AE recurs after talazoparib resumes.
Grade ≥[ADDRESS_534604] or ALT, temporary hold if elevation > 5 ×ULN (ALT or 
AST ≥3 ×ULN w ith the presence of signs and symptoms consistent with acute 
hepatitis and/or eosinophilia 
[≥500 eosinophils/ μL]) until resolves to grade ≤[ADDRESS_534605], temporary hold if elevation > 8 × ULN until 
resolves to grade ≤1 or baseline. Resume talazoparib at the same dose or reduce by 
1 dose level per Table 4.
If baseline Grade 1 bilirubin, temporary hold if elevation >3 ×ULN until resolves to 
grade ≤1or baseline. Resume talazoparib at the same dose or reduce by 1 dose 
level per Table 4.
If baseline Grade 2 bilirubin, temporary hold if elevation >5 ×ULN until resolves 
to grade ≤1 or baseline. Resume talazoparib at the same dose or reduce by 1 dose 
level per Table 4.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 48Table 5. Dose Modification and Management Due to Adverse Reactions
Toxicity Managem ent of Adverse Events 
Nonlaboratory 
grade ≥3 event s Hold talazoparib as follows: 
For clinically significant grade 3 AE s, hold talazoparib until the AEs resolves 
to grade ≤1 or baseline. Resume talazoparib at the same dose or reduce by 1 
dose level per Table4.
For grade 4 AEs, hold talazoparib until the AE resolves to grade ≤[ADDRESS_534606] be 
discontinued if a grade 4 AE r ecurs after treatment resumes.
6.7.Intervention After the End of the Study
No study  intervention will be provided to study participants at the end of the study unless 
otherwise required b y local laws or regulations .
Preparations for study  closure will occur at the collection of the final data point for primary  
and secondary  study  objectives. During study  closure preparations, the sponsor may  work 
with sites to explore options for alternative source of treatment for remaining patients in the 
maintenance phase.
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Intervention
In rare instances, it may  be necessary  for a participant to permanentl y discontinue study  
intervention (definitive discontinuation). Reasons for definitive discontinuation of study  
intervention include the following 
Objective disease progression.
Global deterioration of health status;
Unacceptable toxicity ;
Pregnancy ;
Significant protocol violation;
Lost to follow -up;
Patient refuse d further treatment;
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 49Study  terminated by  [CONTACT_3211]; or
Death.
Note that discontinuation of study  intervention does not represent withdrawal from the study .
If study  intervention is definitively  discontinued, the participant will remain in the study  to 
be evaluated for safet y follow -up until [ADDRESS_534607] be documented on the 
appropriate CRF/in the medical records whether the participant is discontinuing f urther 
receipt of stud y intervention or also from study  procedures, post treatment study  follow -up, 
and/or future collection of additional information.
7.2.Participant Discontinuation/Withdrawal from the Study 
A participant may  withdraw from the study  at an y time at his/her own request. Reasons for 
discontinuation from the study  include the following:
Refused further follow -up;
Lost to follow -up;
Death;
Study  terminated by  [CONTACT_3211].
If a participant withdraws from the study , he/she may  request destruction of an y remaining 
samples taken and not tested, and the investigator must document any  such requests in the 
site study  records and notify  the sponsor accordingly .
If the participant withdraws from the study  and withdraws consent (see Section 7.2.1) for 
disclosure of future information, no further evaluations should be performed and no 
additional data should be collected. The sponsor may  retain and continue to use any  data 
collected before such withdrawal of consent.
Lack of completion of all or an y of the withdrawal/earl y termination procedures will not be 
viewed as protocol deviations so long as the participant’s safet y was p reserved.
7.2.1.
Withdrawal of Consent 
Participants who request to discontinue receipt of IP will remain in the study and must 
continue to be followed for protocol -specified follow -up procedures. The only  exception to 
this is when a participant specificall y with draws consent for any further contact [CONTACT_423183] y authorized by [CONTACT_104140].
Participants should notify  the investigator in writing of the decision to withdraw consent 
from future follow -up, wheneve r possible. The withdrawal of consent should be explained in 
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 50detail in the medical records by [CONTACT_093], as to whether the withdrawal is only  from 
further receipt of study  intervention or also from study  procedures and/or posttreatment study  
follow -up, and entered on the appropriate CRF page. In the event that vital status (whether 
the participant is alive or dead) is being measured, publicly  available information should be 
used to determine vital status only  as appropriately  directed in accordance w ith local law.
7.3.Lost to Follow -up
A participant will be considered lost to follow -upif he or she repeatedl y fails to return for 
scheduled visits and is unable to be contact[INVESTIGATOR_530] b y the study  site.
The following actions must be taken if a participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact [CONTACT_322436]/or should 
continue in the study ;
Before a participant is deemed lost to follow -up, the investigator or designee must 
make every  effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if nec essary , a certified letter to the participant’s last known mailing 
address or local equivalent methods).
These contact [CONTACT_14316]’s medical record;
Should the participant continue to be unreachable, he/she will be cons idered to have 
withdrawn from the study. 
8.STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing an y stud yspecific procedures. Signing of the informed co nsent 
by [CONTACT_423184] .
Study  procedures and their timing are summarized in the SoA.Protocol waivers or 
exemptions are not allowed.
Safety  issues should be discussed with the sponsor immediately  upon occurrence or 
awareness to determine whether the participant should continue or discontinue study  
intervention.
Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for stud y con duct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  orrecord reasons for 
screening failure, as applicable.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 51Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of the ICD may be utilized for screening or baseline 
purposes provided the pro cedures met the protocol specified criteria and were performed 
within the time frame defined in the SoA, except:
The imaging window for eligibility  at screening will be allowed to precede the Period [ADDRESS_534608] of care imaging. 
Any historical diagnostic testing may  be utilized to document mutations, no diagnostic 
testing will be performed in this study .
 Participants will be required to maintain a diary  to capture daily  dosing in real -time, 
date and time of each dose (or missing doses).
 PK shipment requirements will be documented in a Study  Laboratory  Manual.
The total blood sampling volume for individual participants in this study  is approximately  
270 mL  for the BE phase ( 57 days) plus [ADDRESS_534609]. Unplanned procedures or visits per investigator’s discretion 
for safety  management will be reported on the Unscheduled CRFs.
Every  effort should be made to ensure that protocol required tests and procedures are 
completed as described. However, it is anticipated that from time to time there may  be 
circumstances outside the control of the investigator that may  make it unfeasible to perf orm 
the test. In these cases, the investigator must take all steps necessary  to ensure the safet y and 
wellbeing of the participant. When a protocol required test cannot be performed, the 
investigator will document the reason for the missed test and an y corrective and preventive 
actions that he or she has taken to ensure that required processes are adhered to as soon as 
possible. The study  team must be informed of these incidents in a timely  manner.
For samples being collected and shipped, detailed collectio n, processing, storage, and 
shipment instructions and contact [CONTACT_19987] .
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June [ADDRESS_534610] of care and investigators will confirm disease progression has not 
occurred for the participant’s continuation in the study .
8.1.1. Imaging Assessments
Participant swill provide consent for use of their imaging data for participation in this study . 
Standard of care assessments will be utilized for respective tumor diagnosis (but no later than 
every  6-12 months or as clinically  indicated) to monitor for continued bene fit on treatment .
SOC imaging will be utilized for eligibility  and RECI ST criteria will not be reported during 
the study .
8.2.Safety Assessments
Safety  assessments will include collection of AEs, SAEs, vital signs, 12
-lead ECG and 
laboratory  assessments, inclu ding pregnancy  tests. AEs and SAEs will be assessed per NCI 
CTCAE version 5.0.
Planned time points for all safety  assessments are provided in the SoA.Unscheduled clinical 
laboratory  measurements may  be obtained at any  time during the stud y to assess any 
perceived safety  issues.
8.2.1. Physical Examinations
A complete ph ysical examination will include, at a minimum, assessments of the 
cardiovascular, respi[INVESTIGATOR_13521] y, gastrointestinal, and neurological s ystems.
A brief ph ysical examination will include, at a minimum, assessments of the skin, lungs, 
cardiovascular s ystem, and abdomen (liver and spleen).
Investigators should pay  special attention to clinical signs rela ted to previous serious 
illnesses. 
8.2.2. Vital Signs
Oral temperature, pulse /heart
rate, weight , and blood pressure will be assessed. Height will 
be reported at screening.
Blood pressure and pulse rate measurements will be assessed in supi[INVESTIGATOR_423168]/BA Phases and sitting position during the Maintenance Phase with a completely  
automated device. Manual techniques will be used only  if an automated device is not 
available.
Blood pressure and pulse rate measurements should be preceded b y at least [ADDRESS_534611] 
for the participant in a quiet setting without distractions (eg, television, cell phones).
Vital signs (to be taken before blood collection for laboratory  tests) will consist of 1 pulse 
rate and 3 blood pressure measurements ([ADDRESS_534612] 1 minute). The average of the [ADDRESS_534613] 12- lead ECGs utilizing limb leads (with a 10 second rh ythm strip) should be 
collected at times specified in the SoA section of this protocol using an ECG machine that 
automatically  calculates the heart rate and measures PR, QT, and QTc intervals and QRS 
complex. Alternative lead placement methodology using to rso leads (eg, Mason -Likar) is not 
recommended given the potential risk of discrepancies with ECGs acquired using standard 
limb lead placement. All scheduled ECGs should be performed after the participant has 
rested quietly for at least 10 minutes in a sup ine position. 
If a) a post dose QTc interval remains ≥60msec from the baseline and is >470 msec; or b) an 
absolute QTc value is ≥500 msec for an y scheduled ECG for greater than 4 hours (or sooner, 
at the discretion of the investigator); or c) QTc intervals get progressivel y longer, the 
participant should undergo continuous ECG monitoring. A cardiologist should be consulted 
if QTc intervals do not return to less than the criterion listed above after 8 hours of 
monitoring (or sooner, at the discretion of th e investigator). 
In some cases, it may  be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that leads be placed in the 
same positions each time in order to achieve precise ECG recordings. If a machine read QTc 
value is prolonged, as defined above, repeat measurements may  not be necessary  if a 
qualified medical provider’s interpretation determines that the QTc values are in the 
acceptable range.
ECG values of potential clinical c oncern are listed in Appendix [ADDRESS_534614] any  
clinically  relevant changes oc curring during the study  in the AE section of the CRF.
Clinically  significant abnormal laboratory  findings are those which are not associated with 
the underl ying disease, unless judged by  [CONTACT_78259] 's condition.
All laboratory  tests with values considered clinically  abnormal during participation in the 
study  or within 28 (+7) day s after the last dose of study  intervention should be repeated until 
the values return to normal or baseline or are no long er considered clinically  significant by  
[CONTACT_10982].
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 54If such values do not return to normal/baseline within a period of time judged reasonable by  
[CONTACT_093], the etiology  should be identified and the sponsor notified.
See Appendix [ADDRESS_534615] 
25mIU/mL.Pregnancy  tests will be performed in WOCBP at the times listed in the SoA .
Following a negative pregnancy  test result at screening, appropriate contraception must be 
commenced and a second negative pregnancy  test result will be r equired at the baseline visit 
prior the participant’s receiving the IP. Pregnancy  tests will also be done whenever 1 
menstrual cy cle is missed during the active treatment period (or when potential pregnancy  is 
otherwise suspected) and at the end of the stu dy.Pregnancy  tests may  also be repeated if 
requested b y IRBs/ ECs or if required b y local regulations. If a urine test cannot be 
confirmed as negative (eg, an ambiguous result), a serum pregnancy  test is required. In such 
cases, the participant must be ex cluded if the serum pregnancy  result is positive.
8.3. Adverse Events and Serious Adverse Events
The definitions of an AE and an SAE can be found in Appendix 3 .
AEs will be reported b y the participant (or, when appropriate, b y a caregiver, surrogate, or 
the participant's legall y authorized representative). 
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording event s that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
the study  intervention (see Section 7.1). 
Each participant will be questioned about the occurrence of AEs in a nonleading manner.
In addition, the investigator may  be requested by  [CONTACT_19989] y to obtain specific follow -
up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for Collecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before the participant’s participation in the study  (ie, before undergoing 
any study -related procedu re and/or receiving IP), through and including a minimum of [ADDRESS_534616] SAE Report Form.
Investigators are not obligated to activel y seek AEs or SAEs after the participant has 
concluded stud y participation .However, if the investigator learns of any  SAE, including a 
death, at an y time after a participant has completed the study, and he/she considers the event 
to be reasonably  related to the study  intervention, the investigator must promptly  report the 
SAE to [COMPANY_007] us ing the CT SAE Report Form.
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection period as described in 
Section 8.3.[ADDRESS_534617] still be reported to [COMPANY_007] Safety  irrespective of any  intervening 
treatment. Note that a switch to a commerciall y available version of the study intervention is 
considered as a new anticancer therap y for the purposes of SAE reporting.
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent as described in Section 8.3.[ADDRESS_534618] on the CRF all directly  observed and all spontaneously  reported 
AEs and SAEs reported by  [CONTACT_2299].
If a participant begins a new anticancer therap y, the recording period for nonserious AEs 
ends at the time the new treatment is started; however, SAEs must continue to be recorded on 
the CRF during the above
-indicated active collection period. Note that a switch to a 
commerciall y available version of the study intervention is considered as a new anticancer 
therap y for the purposes of SAE reporting.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 568.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 .
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follow -up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. For each event, the investiga tor must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to followup (as defined inSection 7.3).
In general, follow -
up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality .Any information rel evant to the event, such as concomitant medications 
and illnesses, must be provided. In the case of a participant death, a summary of available 
autopsy  findings must be submitted as soon as possible to [COMPANY_007] Safety . 
Further information on follow -up procedures is given in Appendix 3 .
8.3.4. Regulatory Reporting Requirements for SAEs
Prompt notification by  [CONTACT_11012] a SAE is essential so that legal 
obligations and ethical responsibilities tow ards the safet y of participants and the safet y of a n
IP under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRBs/ECs , and investigators.
Investigator safety reports must be prepared for S[LOCATION_003]Rs according to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who receives S[LOCATION_003]Rs or other specific safet y information (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with the S RSD(s) for the 
study  and will notify  the IRB/EC, if appropriate according to local requirements.
8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational Exposure
Exposure to the study  interve ntion under stud y during pregnancy  or breastfeeding and 
occupational exposure are reportable to [COMPANY_007] Safety  within 24 hours of investigator 
awareness.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Exposure During Pregnancy
An EDP occurs if:
A female participant is found to be pregnant while receiving or after discontinuing IP.
A male participant who is receiving or has discontinued I P exposes a female partner 
prior to or around the time of conception.
A female is found to be pregnant while being exposed or having been exposed to I P 
due to environmental ex posure. Below are examples of environmental exposure 
during pregnancy :
A female family  member or healthcare provider reports that she is pregnant after 
having been exposed to the I P by [CONTACT_19991].
A male famil y member or healthcare provide r who has been exposed to the I P by 
[CONTACT_423185].
The investigator must report EDP to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness, irrespective of whe ther an SAE has occurred. The initial information submitted 
should include the anticipated date of delivery  (see below for information related to 
termination of pregnancy). 
If EDP occurs in a participant or a participant’s partner, the investigator must r eport 
this information to [COMPANY_007] Safety on the CT SAE Report Form and an EDP 
Supplemental Form, regardless of whether an SAE has occurred. Details of the 
pregnancy  will be collected after the start of I P and up to [ADDRESS_534619] dose of IP.
If EDP occurs in the setting of environmental exposure, the investigator must report 
information to [COMPANY_007] Safety  using the CT SAE Report Form and EDP Supplemental 
Form. Since the exposure information does not pertain t o the participant enrolled in 
the study , the information is not recorded on a CRF; however, a copy  of the 
completed CT SAE Report Form is maintained in the investigator site file.
Follow -up is conducted to obtain general information on the pregnancy  and it s outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  [COMPANY_007] Safet y of the outcome as a 
follow -up to the initial EDP Supplemental Form. In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth. In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the terminated fetus should be assessed by  [CONTACT_4692] (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 58Abnormal pregnancy  outcomes are considered SAEs. If the outcome of the pregnancy meets 
the criteria for an S AE (ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y (in a live- born bab y, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures 
for reporting SAEs. Additional information about pregnancy  outcomes that are reported to 
[COMPANY_007] Safety  as SAEs follows: 
Spontaneous abortion including miscarriage and missed abortion;
Neonatal deaths that occur within [ADDRESS_534620] 
to causality , as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the study  intervention. 
Additional information regarding the EDP may  be requested by  [CONTACT_456]. Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s).In the case of paternal exposure, the 
investigator will provide the pa rticipant with the Pregnant Partner Release of Information 
Form to deliver to his partner. The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.
[IP_ADDRESS]. Exposure During Breastfeeding
Scenarios of exposure during breastfeeding must be reported, irrespective of the presence of 
an associated SAE, to [COMPANY_007] Safet y within 24 hours of the investigator’s awareness, using the 
CT SAE Report Form. An exposure during br eastfeeding report is not created when a [COMPANY_007] 
drug specifically  approved for use in breastfeeding women (eg, vitamins) is administered in 
accord with authorized use. However, if the infant experiences an SAE associated with such 
a drug’s administration, the SAE is reported together with the exposure during breastfeeding.
An exposure during breastfeeding occurs if: 
A female participant is found to be breastfeeding while receiving or after 
discontinuing I P.
A female is found to be breastfeeding while being exposed or having been exposed to 
IP (ie, environmental exposure). An example of environmental exposure during 
breastfeeding is a female family  member or healthcare provider who reports that she 
is breastfeeding after having been exposed to the IP by  [CONTACT_423186].
The investigator must report exposure during breastfeeding to [COMPANY_007] Safety  within 24 hours 
of the investigator’s awareness, irrespective of whether an SAE has occurred. The 
information must be reported using the CT SAE Report Form . When exposure during 
breastfeeding occurs in the setting of environmental exposure, the exposure information does 
not pertain to the participant enrolled in the study , so the information is not recorded on a 
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June [ADDRESS_534621] SAE R eport Form is maintained in the 
investigator site file.
An exposure during breastfeeding report is not created when a [COMPANY_007] drug specificall y 
approved for use in breastfeeding women (eg, vitamins) is administered in accord with 
authorized use. However, if the infant experiences an SAE associated with such a drug, the 
SAE is reported together with the exposure during breastfeeding.
[IP_ADDRESS]. Occupational Exposure
An occupational exposure occurs when a person receives unplanned direct contact [CONTACT_423187], which may  ormay not lead to the occurrence of an AE. Such persons may  include 
healthcare providers, family  members, and other roles that are involved in the trial 
participant’s care.
The investigator must report occupational exposure to [COMPANY_007] Safet y within 24 hours of the 
investigator’s awareness, regardless of whether there is an associated SAE. The information 
must be reported using the CT SAE Report Form. Since the information does not pertain to a 
participant enrolled in the study, the information is not recorded on a CRF; however, a copy  
of the completed CT SAE Report Form is maintained in the investigator site file.
8.3.6. Cardiovascular and Death Events 
Not a pplicable .
8.3.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs 
Not a pplicable .
8.3.8. Adverse Events of Special Interest 
Not a pplicable .
[IP_ADDRESS]. Lack of Efficacy
This section is not applicable because efficacy  will not be analyzedin the study  population.
8.3.9.
Medical Device Deficiencies 
Not a pplicable .
[IP_ADDRESS]. Prompt Reporting of Device Deficiencies to Sponsor
8.3.10. Medication Errors
Medication errors may  result from the administration or consumption of the I P by [CONTACT_181879], or at the wrong t ime, or at the wrong dosage strength.
Exposures to the I P under study  may  occur in clinical trial settings, such as medication 
errors.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June [ADDRESS_534622] SAE Report 
Form to [COMPANY_007] Safety Within 24 
Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an SAE
Medication errors include:
Medication errors involving participant exposure to the study  intervention;
Lack of dose reduction as specified b y the protocol ;
Continuation of treatment although participant met discontinuation criteria;
Incorrect IP dose b y participant;
Participant did not take IP for 6 or more day s (approximately  <80%) within 4 weeks, 
unless dose was withheld due to an AE;
Participant did not receive treatment as assigned by [CONTACT_12067];
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study  participant.
Such medication errors occurring to a stud y participant are to be captured on the medicat ion 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified within 24 hours .
Whether or not the medication error is accompanied by  [CONTACT_1149], as determined by  [CONTACT_1275], the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are recorded on the A E page of the 
CRF.
Medication errors should be reported to [COMPANY_007] Safety within [ADDRESS_534623] SAE Report 
Form only when associated with an SAE.
8.4.Treatment of Overdose
For this study , any  dose of talazoparib greater than 1 mg within a 24- hour time period will be 
considered an overdose.
[COMPANY_007] does not recommend specific treatment for an overdose. All overdose events are to be 
reported per requirements in Section 8.3.10 .
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 639.1.Estimands and Statistical Hypotheses
9.1.1. Statistical Hypothesis
The alternative hy pothesis of BE (H 1:L<=T-R<=U), and the null hy pothesis of 
inequivalence (H o:T-R<LorT-R>U) can be expressed as the following 2separate 
one-sided h ypotheses:
HoA:T-R<L
H1A:L<=T-R
HoB:T-R>U
H1B:T-R<=U
where TandRrepresent the average bioavailability  on a log scale for the Test and 
Reference products respectively  and [L,U] defines the BE range.
The 2 one- sided h ypotheses will be tested at the = 0.05 levels of significance for log 
transformed AUC 24and C maxby [CONTACT_31362] 90% CIfor the ratio between the test and 
reference geometric means .
9.2. Sample Size Determination
Itis estimated that 22 participants will be required to provide 90% power that the 90% CIfor 
the Test/Reference ratio of talazoparib AUC 24fallswithin the 80‑125% acceptance interval 
for bioequivalence. Additionally , with [ADDRESS_534624]/Reference ratio 
forCmaxwill fall within 80% -125% is estimated to be 86%. Theseestimate sarebased on the 
assumption that the true ratio between Test and Reference treatments for AUC 24and C maxis 
1.[ADDRESS_534625] evaluation phase .The i nitial number of 46participants is 
estimated based on 52% non-evaluable rate and might be adjusted during enrollment if non-
evaluable 
rate changes. The criteria for PK-evaluability  will be described in detail in the 
SAP.
When approximately  12 evaluable participants complete both Periods 1 and 2, initial 
assumptions (AUC 24variability and point estimate) for power/sample size calculation may  be 
reassessed
. Sample size may be increased; however ,the total number of participants to be 
enrolled in the study  may  not exceed approximately  88 participants.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 649.3.Analysis Sets
For purposes of analysis, the following analysis sets are defined:
Participant Analysis Set Description
PK Concentration The PK concentration population is defined as all 
participants randomized and treated who have at least [ADDRESS_534626] ical analy ses of the primary  and secondary  
endpoints.
9.4.1. General Considerations
Methodology for summary  and statistical anal yses of the data collected in this study  is 
outlined here and further detailed in a SAP, which will be maintained by  [CONTACT_456]. The 
SAP may  modify  what is outlined in the protocol where appropriate; however, any  major 
modifications of the primary  endpoint definitions or their anal yses will also be reflected in a 
protocol amendment.
9.4.2. Primary Endpoint(s)
To assess BE, natural log transformed AUC 24and C maxafter multiple dosing on the last day  
of Period [ADDRESS_534627]. Estimates of 
the adjusted mean d ifferences (Test ‑Reference) and corresponding 90% CIs will be obtained 
from the model. The adjusted mean differences and 90% CI s for the differences will be 
exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) 
and 90% CIs for the ratios. Treatment A (commercial formulation given under fasting 
condition) will be the Reference treatment while Treatment B (the proposed talazoparib soft 
gel capsule formulation under fasting condition) will be the Test treatment.   
To assess food effect, natural log transformed AUC 24and C maxafter multiple dosing on the 
last day  of Treatment B and C will be analy zed using a mixed effect model with sequence 
and treatment as fixed effects and participant within sequence as a random effect .Estimates 
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 65of the adjusted mean differences (Test ‑Reference) and corresponding 90% CI s will be 
obtained from the model. The adjusted mean differences and 90% CIs for the differences will 
be exponentiated to provide estimates of the ratio of adjusted geome tric means 
(Test/Reference) and 90% CIs for the ratios. Treatments B (the proposed talazoparib soft gel 
capsule formulation under fasting condition) is the Reference treatment while Treatments C 
(the proposed talazoparib soft gel capsule formulation given with high -fat/high- calorie meal) 
is Test treatment.
If initial design assumptions are reassessed during the trial, additional sensitivity  anal ysis of 
BE will be performed b y combining estimators from 2 stages using Cui, Hung, Wang [ZIP_CODE]. 
The 90% CI will be constructed using combined weighted estimate and standard error from 
2stages.1
9.4.3. Secondary Endpoint(s)
The PK parameters AUC 24, AUC last,Cmax, Ctrough, CL/F,and Tmaxon the last day  of Period 1 
to 3 will be summarized descriptivel y by [CONTACT_3148]. Concentrations will be listed and 
summarized descriptively b y treatment, and PK sampling time. Individual participant and 
median profiles of the concentration ‑time data will be plotted by  [CONTACT_3148]. For summary  
statistics and median plots by  [CONTACT_31065], the nominal PK sampling time will be used. For 
individual participant plots by [CONTACT_5586], the actual PK sampling time will be used.
Ctrough on 3
consecutive day s will be compared to assure steady  state is reached. 
[IP_ADDRESS]. Pharmacokinetic Analyses
Derivation of Pharmacokinetic Parameters
Parameter Definition Method of Determination
AUC [ADDRESS_534628] day 
of treatment period 1 to 3Linear/Log trapezoidal method
AUC lastaArea under the plasma 
concentration -time profile from 
time zero to the time of the last 
quantifiable
concentration (Clast) on the last 
day of treatment period 1 to 3Linear/Log trapezoidal method
Cmax Maximum plasma concentration 
on the last day of treatment period 
[ADDRESS_534629] occurrence
CtroughbPredose plasma drug 
concentration Observed directly from data
CL/F Apparent clearance after oral dose 
on the last day of treatment period 
1 to 3Dose/ AUC [ADDRESS_534630] measurable PK sample is not taken at 24 hours postdose.
b.Predose sample from a PK -evaluable participant
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 6710. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki an d CIOMS International Ethical Guidelines;
Applicable ICH GCP guidelines;
Applicable laws and regulations, including applicable privacy  laws.
The protocol, protocol amendments, I CD, SRSD(s), and other relevant documents (eg, 
advertisements) must be reviewed and approved by  [CONTACT_20002] I RB/EC 
by [CONTACT_20003] b y the IRB/EC before the study  is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the stud y design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accor dance with the requirements, policies, and procedures 
established by  [CONTACT_1201]/EC;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by 
[CONTACT_1744]/EC procedures;
Providing oversight of the conduct of the stud y at the site and adherence t o 
requirements of 21 CFR, ICH guidelines, the IRB/EC, European regulation 536/2014 
for clinical studies (if applicable), and all other applicable local regulations.
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of any prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of an y new 
information that might influence the evaluation of the benefits and risks of the study 
intervention, [COMPANY_007] should be informed immediately . 
In addition, the investigator will inform [COMPANY_007] immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study participants against an y immediate hazard, and 
of an y serious breaches of this protocol or of ICH GCP that the investi gator becomes aware 
of.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 6810.1.2. Financial Disclosure
Investigators and sub-investigators will provide the sponsor with sufficient, accurate 
financial information as requested to allow the sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities.
Investigators are responsible for providing information on financial interests during the 
course of the stud y and for 1 y ear after completion of the study .
10.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study  to the 
participant or his/her legally  authorized representative and answer all questions regarding the 
study .The participant or his/her legally  authorized representative should be given sufficie nt 
time and opportunity  to ask questions and to decide whether or not to participate in the trial.
Participants must be informed that their participation is voluntary .Participants or their 
legally  authorized representative defined as an y individual person , judicial body  or other of 
individuals who are legally  authorized under state and federal law to consent to research 
participation on behalf of a designated person will be required to sign a statement of 
informed consent that meets the requirements of 21 CFR 50, local regulations, I CH 
guidelines, HI PAA requirements, where applicable, and the IRB/EC or study  center.
The investigator must ensure that each study  partic ipant or his or her legally  authorized 
representative is fully  informed about the nature and objectives of the study , the sharing of 
data related to the study , and possible risks associated with participation, including the risks 
associated with the processing of the participant’s personal data. 
The participant must be informed that his/her personal study -related data will be used by  [CONTACT_20004]. The level of disclosure must also be 
explained to the participant.
The participant must be informed that his/her medical records may  be examined by  [CONTACT_160439], by  
[CONTACT_6667]/EC members, and b y inspectors from regulatory authorities.
The investigator further must ensure that each study  participant or his or her legall y 
authorized representative is fully  informed about his or her right to access and correct his or 
her personal data and to withdraw consent for the processing of his or her pe rsonal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study
 and the date the written consent was obtained.
The authorized person obtaining the informed consent must also sign the ICD.
Participants must be reconsented to the most current version of the ICD(s) during their 
participation in the study .
A cop y of the ICD(s) must be provided to the participant or the participant’s legall y 
authorized representative.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 69A participant who is rescreened is not required to sign another ICD if the rescreening occurs 
within 30 day s from the previous ICD signature [CONTACT_568].
Unless prohibited by [CONTACT_20006]/EC decision, the I CD will contain a separate 
section that addresses the use of samples for optional additional research. The optional 
additional research does not require the collection of an y further samples. The investigator or 
authorized designee will explain to each participant the objectives of the additional research.
Participants will be told that they  are free to refuse to participate and may  withdraw their 
consent at an y time and for any reason during the storage period.
10.1.4. Data Protection
All parties will comply  with all applicable laws, including laws regarding the imp lementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in encry pted electronic and/or paper 
form and will be password protected or secured in a locked room to ensure that only  
authorized study  staff have access. The stud y site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster. In the event of a potential personal data b reach, the study  site will be responsible for 
determining whether a personal data breach has in fact occurred and, if so, providing breach 
notifications as required by  [CONTACT_2371].
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specific numerical code. Any 
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other iden tifiable data transferred to the 
sponsor will be identified by  [CONTACT_20007], participant -specific code. The study  site will 
maintain a confidential list of participants who participated in the study , linking each 
participant’s numerical code to his or her a ctual identity  and medical record identification. In 
case of data transfer, the sponsor will protect the confidentiality  of participants’ personal data 
consistent with the clinical study  agreement and applicable privacy  laws.
10.1.5. Dissemination of Clinical Stud y Data
[COMPANY_007] fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer.com, and other public registries in accordance with appl icable local 
laws/regulations. In addition, [COMPANY_007] reports study  results outside of the requirements of local 
laws/regulations pursuant to its SOPs.
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the study  or the country  in 
which the study  was conducted.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 70www.clinicaltrials.gov
[COMPANY_007] posts clinical trial results on www.clinicaltrials.gov for [COMPANY_007] -sponsored interventional 
studies (conducted in patie nts) that evaluate the safety  and/or efficacy  of a product, 
regardless of the geographical location in which the study  is conducted. These results are 
submitted for posting in accordance with the format and timelines set forth by  [CONTACT_20008].
EudraCT
[COMPANY_007] posts clinical trial results on EudraCT for [COMPANY_007]- sponsored interventional studies in 
accordance with the format and timelines set forth by  [CONTACT_20009].
www.pfizer.com
[COMPANY_007] posts public disclosure s ynopses (CSR synopses in which an y data that could be used 
to identify  individual participants have been removed) on www.pfizer.com for 
[COMPANY_007] -sponsored interventional studies at the same time the corresponding study  results are 
posted to www.clinicaltrials.gov.
Documents within marketing authorization pac kages/submissions
[COMPANY_007] complies with the European Union Policy  0070, the proactive publication of clinical 
data to the EMA website. Clinical data, under Phase 1 of this policy , includes clinical 
overviews, clinical summaries, CSRs, and appendices containing the protocol and protocol 
amendments, sample CRFs, and statistical methods. Clinical data, under Phase 2 of this 
policy , includes the publishing of individual participant data. Policy  0070 applies to new 
marketing authorization applications submitted via the centralized procedure since 
01January 2015 and applications for line extensions and for new indications submitted via 
the centralized procedure since 01 July  2015.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 71Data Sharing
[COMPANY_007] provides researchers secure access to patient- level data or full CSRs for the purposes 
of “bona -fide scientific research” that contributes to the scientific understanding of the 
disease, target, or compound class. [COMPANY_007] will make available data from these trials 
24months after study  completion. Patient- level data will be anon ymized in accordance with 
applicable privacy  laws and regulations. CSRs will have personally  identifiable information 
redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analy ses.Research teams must include a biostatistician. Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.6. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and correct by  [CONTACT_20010].
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must ensure that the CRFs are securel y stored at the study site in encrypted 
electronic and/or paper form and are password protected or secured in a locked room to 
prevent access b y unauthorized third parties.
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide dir ect access to source data documents. This 
verification may  also occur after study  completion. It is important that the investigator(s) and 
their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that suffi cient time is devoted to the process.
Monitoring details describing strategy  (eg, risk- based initiatives in operations and quality  
such as risk management and mitigation strategies and anal ytical risk- based monitoring), 
methods, responsibilities, and requi rements, including handling of noncompliance issues and 
monitoring techniques (central, remote, or on -site monitoring), are provided in the study  
monitoring plan and respective monitoring vendor contract.
The sponsor or designee is responsible for the data management of this study , including 
quality  checking of the data.
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study  is 
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June [ADDRESS_534631] ensure that the records continue to be stored sec urely for as long as they are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_78245] y deleted from all systems.
The investigator(s) will notify  the sponsor or its agents im mediately  of any  regulatory  
inspection notification in relation to the study .Furthermore, the investigator will cooperate 
with the sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site and investigator will promptly  resolve any  discrepancies that are identified 
between the stud y data and the participant's medical records. The investigator will promptly  
provide copi[INVESTIGATOR_19946]. Before response 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to an y such findings.
10.1.7. Source Docu ments
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source documents are filed at the investigator site.
Data reported on the CRF or entered in the eCRF that are from source doc uments must be 
consistent with the source documents or the discrepancies must be explained. The 
investigator may  need to request previous medical records or transfer records, depending on 
the study . Also, current medical records must be available.
Definiti on of what constitutes source data can be found in Study  Manual and/or CRF 
Guidelines.
Description of the use of computerized sy stem is documented in the Data Management Plan .
10.1.8. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruitment of 
participants.
The first act of recruitment is the date of the first participant’s first visit and will be the study  
start date.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June [ADDRESS_534632] been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time upon notification to the CRO if 
requested to do so b y the responsible IRB/EC or if such termination is required to protect the 
health of study  participants.
Reasons for the early closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or GCP guidelines;
Inadequate re cruitment of participants by  [CONTACT_093];
Discontinuation of further study  intervention development.
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the ECs/IRBs, the regulatory  authorities, and an y CRO(s) used in the study of 
the reason for termination or suspension, as specified by  [CONTACT_20013]. The investigator shall promptly  inform the participant and should assure 
appropriate participant therap y and/or follow -up.
Study  termination is also provided for in the clinical study  agreement. If there is an y conflict 
between the contract and this protocol, the contract will control as to termination rights.
10.1.9. Publication Policy
The results of this study  may  be published or p resented at scientific meetings b y the 
investigator after publication of the overall study  results or 1 y ear after the end of the study  
(or study  termination), whichever comes first. 
The investigator agrees to refer to the primary  publication in any  subse quent publications 
such as secondary  manuscripts, and submits all manuscripts or abstracts to the sponsor 
30days before submission. This allows the sponsor to protect proprietary  information and to 
provide comments and the investigator will, on request, r emove an y previously  undisclosed 
confidential information before disclosure, except for an y stud y-or [COMPANY_007] 
intervention -related information necessary  for the appropriate scientific presentation or 
understanding of the study  results.
For all publications relating to the stud y, the investigator will compl y with recognized ethical 
standards concerning publications and authorship, including those established by  [CONTACT_19483].
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June [ADDRESS_534633] editorial and ethical practice, the 
sponsor will support publication of multicenter studies only  in their entirety and not as 
individual site data. In this case, a coordinating investigator [INVESTIGATOR_78246].
Authorship of publications for the overall study  results will be determined by  [CONTACT_78275] I nternational Committee of Medical Journal Editors authorship 
requirements. 
If publication is addressed in the clinical study  agreement, the publication policy  set out in 
this section will not apply.
10.1.10. Sponsor’s Qualified Medical Personnel
The contact [CONTACT_1133]'s appropriately  qualified medical per sonnel for the 
study  is documented in the study  contact [CONTACT_423188] (SToD) 
system.
To facilitate access to appropriatel y qualified medical personnel on stud y-related medical 
questions or problems, participants are provided with a contact [CONTACT_20016]. The contact [CONTACT_4662], at a minimum, protocol and study  intervention identifiers, 
participant numbers, contact [CONTACT_22850], and contact [CONTACT_4664] a 
contact [CONTACT_423189] t the investigator site staff cannot be reached to provide advice 
on a medical question or problem originating from another healthcare professional not 
involved in the participant’s participation in the study .The contact [CONTACT_423190]; however, it 
should be used only  in the event that the established communication pathway s between the 
investigator site and the study  team are not available. It is therefore intended t o augment, but 
not replace, the established communication pathway s between the investigator site and the 
study  team for advice on medical questions or problems that may  arise during the study .The 
contact [CONTACT_8865] b y the participant d irectl y, and if a participant calls 
that number, he or she will be directed back to the investigator site.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 7510.2. Appendix 2: Clinical Laboratory Tests
The following safet y laboratory  tests will be performed at times defined in the SoA section of 
this protocol. Additional laboratory  results may  be reported on these samples as a result of 
the method of anal ysis or the ty pe of anal yzer used by  [CONTACT_20019] , or as derived 
from calculated values. These additional tests would not requi re additional collection of 
blood. Unscheduled clinical laboratory  measurements may  be obtained at any  time during the 
study  to assess an y perceived safet y issues.
Table 6. Protocol -Required Safety Laboratory Assessments
Hem atology Chemistry Urinalysis Other
Hem oglobin
Hem atocrit
RBC count
Platelet count
WBC count
Total neutrophils (Abs)
Eosinophils (Abs)
Monocytes (Abs)
Basophils (Abs)
Lymphocytes (Abs)BUN and creatinine
Glucose 
Calcium
Sodium
Potassium
Magnesium
Chloride
Total CO 2(bicarbonate)
AST, ALTd
Total bilirubin
Alkaline phosphatase
Uric acid
Albumind
Phosphorus or phosphate
Total protein
Direct/Indirect BilirubinpH
Glucose (qual)
Protein (qual)
Blood (qual)
Ketones
Nitrites
Leukocyte esterase
Urobilinogen
Urine bilirubin
MicroscopyaPregnancy test (β -hCG)c
At screening only:
Coagulation (INR PT, 
aPTT) or as clinically 
indicated
FSHb
a.Only if urine dipstick is positive for blood, protein, nitrites, or leukocyte esterase.
b.For confirmation of postmenopausal status only.
c.Local urine testing will be standard for the protocol unless serum testing is required by [CONTACT_216483]/EC. Serum or urine -hCG for female participants of childbearing potential with sensitivity of at 
least 25 IU/mL.
d.For potential Hy's Law cases, in addition to repeating AST and ALT, laboratory tests should include 
albumin, creatine kinase, total bilirubin, direct and indirect bilirubin, gamma glutamyl transferase, INR 
international normalized ratio, alkaline phosphatase.
Investigators must document their review of each laboratory  safet y report.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 8310.4. Appendix 4: Contraceptive Guidance
10.4.1. Male Participant Reproductive Inclusion Criteria
Male participants are eligible to participate if they  agree to the following requirements during 
the intervention period and for at least [ADDRESS_534634] dose of study intervention , 
which corresponds to the time needed to eliminate reproductive safet y risk of the study  
intervention (s):
Refrain from donating sperm.
PLUS either :
Be abstinent from heterosexual intercourse with a female of childbearing potential as 
their preferred and usual li festy le (abstinent on a long -term and persistent basis) and 
agree to remain abstinent. 
OR
Must agree to use a male condom when engaging in any  activity  that allows for 
passage of ejaculate to another person.
In addition to male condom use, a highl y effec tive method of contraception may  be 
considered in WOCBP partners of male participants (refer to the list of highly  
effective methods below in Section 10.4.[ADDRESS_534635] 1 of the following conditions applies:
Is not a WOCBP (see definitions below in Section 10.4.3).
OR
Is a WOCBP and using a contraceptive method that is highly  effective (with a 
failure rate of <1% per year), as described below, during the intervention period 
and for at least [ADDRESS_534636] dose of study  intervention, which 
corresponds to the time needed to eliminate a ny reproductive safety  risk of the 
study  intervention(s). If a highl y effective method that is user dependent is 
chosen, 
a second effective method of contraception, as described below, must also
be used. The investigator should evaluate the effectiveness of the contraceptive 
method in relationship to the first dose of stud y intervention.
The investigator is responsible for review of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a woman with an earl y undetected 
pregnancy . 
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 8410.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstr ual cy cle cannot 
be confirmed before the first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are notconsidered WOCBP:
1.Premenopausal female with 1 of the following:
Documented h ysterectomy ;
Docume nted bilateral salpi[INVESTIGATOR_1656] ;
Documented bilateral oophorectom y.
For individuals with permanent infertility  due to an alternate medical cause other than the 
above, (eg, mullerian agenesis, androgen insensitivity), investigator discretion should be 
applied to determining study  entry .
Note: Documentation for any of the above categories can come from the site personnel’s 
review of the participant’s medical records, medical examination, or medical history  
interview. The method of documentation should be recorded in the participant’s medical 
record for the stud y.
2.Postmenopausal female:
A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. In addition, a
high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years of age and not using hormonal 
contraception or HRT. 
Female on HRT and whose menopausal status is in doubt will be required to 
use one of the nonestrogen hormonal highl y effective contraception methods
if they  wish to continue their HRT during the study .Otherwise, they  must 
discontinue HRT to allow confirmation of postmenopausal status before study  
enrollment.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 8510.4.4. Contraception Methods
Contraceptive use b y men or women should be consistent with local ava ilability /regulations 
regarding the use of contraceptive methods for those participating in clinical trials.
1.Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation.
2.Intrauterine device.
3.Intrauterine hormone -releasing sy stem.
4.Bilateral tubal occlusion.
5.Vasectomized partner:
Vasectomized partner is a highl y effective contraceptive method provided that the 
partner is the sole sexual partner of the woman of childbearing potential and the 
absence of sperm has been confirmed .If not, an additional highly effective 
method of contraception should be used. The spermatogenesis cy cle is 
approximately  90 day s.
6.Combined (estrogen- and progestogen -containing) hormonal contraception associated 
with inhibition of ovulation:
Oral;
Intra vaginal;
Transdermal;
Injectable.
7.Progestogen -only hormone contraception associated with inhibition of ovulation:
Oral;
Injectable.
8.Sexual abstinence:
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention. The reliability  of sexual abstinence needs to be 
evaluated in relation to the duration of the stud y and the preferred and usual 
lifesty le of the participant.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June [ADDRESS_534637] also be used when 
option 6 or 7 are chosen above:
Male or female condom with or without spermicide;
Cervical cap, diaphragm, or sponge with spermicide;
A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods).
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 8810.6. Appendix 6: Liver Safe ty: Suggested Actions and Follow -up Assessments 
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  [CONTACT_20023]) are termed “tolerators,” while those who show transient l iver injury , but adapt 
are termed “adaptors.” In some participants, transaminase elevations are a harbinger of a 
more serious potential outcome. These participants fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury, commo nly referred to as DILI.
Participants who experience a transaminase elevation above 3 ×ULN should be monitored 
more frequently  to determine if they  are an “adaptor” or are “susceptible.”
In the majority  of DILI cases, elevations in AST and/or ALT precede TBili elevations (>2 ×
ULN) b y several days or weeks. The increase in TBili ty pi[INVESTIGATOR_1306] y occurs while AST/ALT is/are 
still elevated above 3 ×ULN (ie, AST/ALT and TBili values will be elevated within the same 
laboratory  sample). In rare instances, b y the time TBili elevations are detected, AST/ALT 
values might have decreased. This occurrence is still regarded as a potential DILI. Therefore, 
abnormal elevations in either AST OR ALT in addition to TBili that meet the criteria 
outlined below are considered potential DILI (assessed per Hy ’s law criteria) cases and 
should alway s be considered important medical events, even before all other possible causes 
of liver injury  have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant’s individual baseline values and underlying conditions. Participants who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participants with AST/ALT and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participants with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or 
ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).
Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at le ast 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).
Rises in AST/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June [ADDRESS_534638] and AL T and TBili for suspected cases of 
Hy’s law, additional laboratory  tests should include albumin, CK, direct and indirect 
bilirubin, GGT, PT/I NR, total bile acids, and alkaline phosphatase. Consideration should also 
be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood for 
further testing, as needed, for further contemporaneous anal yses at the time of the recognized
initial abnormalities to determine etiology .A detailed history , including relevant information, 
such as review of ethanol, acetaminophen/paracetamol (either b y itself or as a coformulated 
product in prescription or over -the-counter medications) , recreati onal drug, supplement 
(herbal) use and consumption, family  history , sexual history , travel history, history  of contact 
[CONTACT_4490] a jaundiced person, surgery , blood transfusion, history  of liver or allergic disease, and 
potential occupational exposure to chemica ls, should be collected. Further testing for acute 
hepatitis A, B, C, D, and E infection and liver imaging (eg, biliary  tract) and collection of 
serum samples for acetaminophen /paracetamol drug and/or protein adduct levels may  be 
warranted. 
All cases demo nstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonabl e investigations have been received and have excluded an alternative etiology .
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 9210.8. Appendix 8: Alternative Measures During Public Emergencies
Thealternative study  measures described in this section areto be followed during public 
emergencies, including the COVID -19 pandemic. This appendix applies for theduration of 
the COVID -19 pandemic at specific location(s) and will become effective for other public 
emergencies onl y upon written notification from [COMPANY_007]. 
Use of these alternative study  measures are expected to cease upon t he return of business as 
usual circumstances (including the lifting of an y quarantines and travel bans/advisories).
10.8.1. Eligibility
While SARS -CoV2 testing is not mandated for this study , local clinical practice standards for 
testing should be followed. A pati ent could be excluded if he/she has a positive test result for 
SARS -CoV2 infection, is known to have as ymptomatic infection, or is suspected of having 
SARS -CoV2. Patients with active infections are excluded from study  participation as per 
exclusion criteria 4 (active infection requiring therapy ) and exclusion 16 ( positive CoVI D-[ADDRESS_534639] ). 
10.8.2. Telehealth Visits
In the event that in-clinic study  visits cannot be conducted, every  effort should be made to 
follow up on the safet y ofstudy participants at scheduled visits per the Schedule of 
Activities or unscheduled visits. Telehealth visits ma y be used to continue to assess 
participant safety  and collect data points. Telehealth includes the exchange of healthcare 
information and services via telecommunication technologies (eg, audio, video, 
video- conferencing software) remotel y, allowing the pa rticipant and the investigator to 
communicate on aspects of clinical care, including medical advice, reminders, education, and 
safet y monitoring. The following assessments must be performed during a telehealth visit:
Review and record stud y intervention(s) , including compliance and missed doses.
Review and record an yAEs andSAEs since the last contact. Refer to Section 8.3.
Review and record an y new concomitant medications or changes in concomitant 
medications since the last contact.
Review and record contraceptive method and results of pregnancy testing. Confirm 
that the participant is adhering to the contraception method(s) required in the 
protocol .Refer to Appendix 4and Section [IP_ADDRESS] of this appendix regarding 
pregnancy  tests.
Study  participants must be reminded to promptl ynotify site staff about an y change in their 
health status.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 9310.8.3. Alternative Facilities for Safety Assessments
[IP_ADDRESS]. Laboratory Testing
If a stud y participant is unable to visit the site for protocol -specified safety  laboratory  
evaluations, testing may beconducted at a local laboratory  if permitted by  [CONTACT_427].
The local laboratory  may be a standalo ne institution or within a hospi[INVESTIGATOR_307]. The following 
safet y laboratory  evaluations may  be performed at a local laboratory :
Blood draw for hematology  and blood chemistry
Urine sample collection
Pregnancy  test
If a local laboratory  is used, qualified stud y site personnel must order, receive, and review 
results. Site staff must collect thelocal laboratory  reference ranges and certifications/
accreditations for filing at the site. Laboratory test results are to be provided to the site staff 
as soon as possibl e.Study  participants should be instructed to collect their laboratory  test 
results and bring them to the next in -clinic visit . The local laboratory  reports should 
be filed in the participant’s source documents/medical records. Relevant data from the local
laboratory  report should be  recorded on the CRF. 
If a participant requiring pregnancy  testing cannot visit a local laboratory  for pregnancy  
testing, a home urine pregnancy  testing kit with a sensitivity  of at least 25 IU/mL  may  be 
used by  [CONTACT_31823] t to perform the test at home, if compliant with local regulatory  
requirements. The pregnancy  test outcome should be documented in the participant’s source 
documents/medical records and relevant data recorded on the CRF. Confirm that the 
participant is adh ering to the contraception method(s) required in the protocol
.
[IP_ADDRESS]. Imaging
Not A pplicable
[IP_ADDRESS]. Electrocardiograms
If the participant is unable to visit the study  site for ECGs, the participant may  visit an 
alternative facility  to have the ECGs performed. Qualified 
study  site personnel must order, 
receive, and review results. 
10.8.4. Study In tervention
If the safet y of a trial participant is at risk because they cannot complete required evaluations 
or adhere to critical mitigation steps, then discontinuing that participant from study  
intervention must be considered.
Talazoparib may beshipped by [CONTACT_423191]. [COMPANY_007] does 
not permit the shipment of talazoparib b y mail. The tracking record of shipments and the 
chain of custod y oftalazoparib must be kept in the participant’s source documents/medical 
records.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June [ADDRESS_534640] active confirmed (positive by  [CONTACT_407604] -approved test) or presumed (test 
pending/clinical suspi[INVESTIGATOR_2798]) SARS- CoV2 infection:
For s ymptomatic participants with active SARS -CoV2 infection, talazoparib should be 
delay ed for at least 14 day s from the start of s ymptoms. This delay  is intended to allow 
the resolution of sy mptoms of SARS -CoV2 infection.
Prior to restarting treatment, the participant should be afebrile for [ADDRESS_534641] recovered to ≤ Grade 1 for a minimum of 72 
hours. Notify  the study  team when treatment is restarted.
Continue to consider potential drug -drug interactions as described in Section 6.5for 
any concomitant medication administered for treatment of SARS -CoV2 infection.
10.8.5. Home Health Visits
A home health care service may beutilized to facilitate scheduled visits per the Schedule of 
Activities. Home health visits include a healthcare provider conducting an in- person study  
visit at the participant’s location, rather than an in -person stud y visit at the site. The 
following may  be performed during a home health visit:
Physical exam
Blood pressure, heart rate, temperature, and weight assessments
Blood draw for hematology  and blood chemistry
Urine sample collection
Pregnancy  test
Contraception check
IP compliance check, accountability , and dispensation
Adve rse event monitoring
Concomit ant medication monitoring
10.8.6. Adverse Events and Serious Adverse Events
If a participant has COVID -19 during the study , this should be reported as an AE or SAE and 
appropriate medical intervention provided. Study  treatment should continue unless the 
investigator/treating ph ysician is concerned about the safety of the participant, in which case 
temporary  or permanent discontinuation may  be required.
It is recommended that the investigator discuss temporary  or permanent discontinuat ion of 
study  intervention with the study  medical monitor.
10.9. Appendix 9: List of Long Half -Life Drugs with No Potential for Drug Interaction 
with Talazoparib
The following treatments with half- lives greater than [ADDRESS_534642] a 30 -day washout period prior to randomization: 
bevacizumab, fulvestrant, ipi[INVESTIGATOR_12458], nivolumab, pembrolizumab, ramucirumab, and 
trastuzumab. For drugs with long half -lives (>6 day s) not included in the list above, consult 
with the sponsor regarding DDI potential.
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 9510.10. Appendix 10: Abbreviations
The following is a list of abbreviations that may  be used in the protocol.
Abbreviation Term
Abs absolute
AE adverse event
AIDS acquired immunodeficiency  syndrome
ALK anaplastic l ymphoma kinase
ALT alanine aminotransferase
AML acute m yeloid leukemia
ANC absolute neutrophil count
aPTT activated partial thromboplastin time
AST aspartate aminotransferase
AUC area under concentration -time curve
AUC [ADDRESS_534643] cancer resistance protein
BE bioequivalence
-hCG -human chorionic gonadotropin
BID twice dail y
bpm beats per minute
BRAF B-Raf proto -oncogene
BRCA BReast CAncer gene
BUN blood urea nitrogen
CAP College of American Pathologists
CFR Code of Federal Regulations
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CL clearance
CLCR creatine clearance
CL/F apparent clearance of drug from plasma
CLIA Clinical L aboratory  Improvement Amendments
Cmax maximum plasma concentration
CO 2 carbon dioxide (bicarbonate)
CoVI D-[ADDRESS_534644]
HIV human immunodeficiency virus
HPMC hydroxypropyl methy l cellulose
HR heart rate
HRT hormone replacement therap y
IB investigator’s brochure
ICD informed consent document
ICH International Council for Harmonisation
ID identification
IMP investigational medicinal product
IND Investigational New Drug
INR international normalized ratio
IP investigational product
IP manual investigational product manual
IPAL Investigational Product Accountability  Log
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June [ADDRESS_534645]
log e base-e logarithm
MDS myelodysplastic s yndrome
MedDRA Medical Dictionary  for Regulatory  Activities
msec millisecond
MX1 myxovirus resistan ce1
n number of participants
N/A not applicable
NDA New Drug Application
NIMP noninvestigational medicinal product
NSCL C non-small cell lung cancer
PARP poly ADP -ribose poly merase
PARPi [INVESTIGATOR_423169]
P-gp P-glycoprotein
PK pharmacokinetic(s)
PO taken b y mouth
PT prothrombin time
PUD peptic ulcer disease
P#D# Period # Day  #
PVC premature ventricular contraction/complex
QD once dail y
QTc corrected QT interval
QTcF QTc corrected using Fridericia’s formula
qual qualitative
RBC red blood cell
RECI ST Response Evaluation Criteria in Solid Tumor
ROS1 c-ros oncogene [ADDRESS_534646] operating procedure
SRSD single -reference safet y document
SToD study  team on demand
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 98Abbreviation Term
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction
t1/[ADDRESS_534647] upper limit of normal
US [LOCATION_002]
USPI [INVESTIGATOR_423170]/F apparent volume of distribution during the terminal phase
WBC white blood cell
WOCBP woman of childbearing potential
Talazopa rib
Protocol C3441037
Final Protocol Amendment 1, 22June 2021
PFIZER CONFIDENTIAL
Page 9911.REFERENCES
1. Cui L , Hung HM, Wang SJ , et al . Modification of sample size in group sequential 
clinical trials. Biometrics . 1999, 55:853 -7. 
2. LYNPARZA® prescribing information. Wilmington, DE : [COMPANY_008]; 2020 . 
Available from: www.lynparza.com/. Accessed: 09 March 2020
3. R ubraca® (rucaparib) prescribing information. Doulder, CO: Clovis Oncology , Inc, 
2020. Available from: www.rubraca.com/. Accessed: 09 March 2020
4. Zejula® (niraparib) prescribing information. Research Triangle Park, NC: 
GlaxoSmithKline; 2020 . Available from: www.zejula.com/. Accessed: 09 March 2020
5.
Talazoparib prescribing information. N ew York, NY :[COMPANY_007], I nc, 2020. Available from : 
www.talzenna.com/ . Accessed: 09 March 2020
6. US Food and Drug Administration. Guidance for industry :Assessing the Effects of 
Food on Drugs in INDs and NDAs 
-Clinical Pharmacology  Considerations Guidance 
for Industry . Available from: www.fda.gov/media/121313/download .Accessed :10 June 
2020